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Abstract 
 
Current clinical practice relies on sufficiently low haemoglobin (HB) level, 
low serum ferritin (SF), low serum iron concentration and an elevated total 
iron binding capacity (TIBC) to identify iron deficiency (ID) and iron 
deficiency anaemia (IDA). However, these parameters are sometimes not 
reliable in assessing iron status in patients with underlying conditions like 
chronic diseases, malignancies and inflammation. Growing evidence 
indicates the appropriate inclusion of reticulocyte haemoglobin content 
(RET-He) and red cell haemoglobin content (RBC-He) into the iron studies 
investigation could improve the early diagnosis. The aim of this study were 
to evaluate the extent to which RET-He and RBC-He values could improve 
the assessment of iron status in chronic disease and inflammation, and to 
evaluate if the inclusion could be used to preclude the need for further 
biochemical assessment in iron status. 
 
A total of 800 samples (89 normal, 611 patients and 100 
haemochromatosis) were obtained and analysed for biochemical and 
haematological iron indicators. RET-He and RBC-He were added to the full 
blood counts parameters on the Sysmex XE2100TM, and C-reactive protein 
was added to indicate inflammation. The inclusion criteria were based on 
symptomatic and asymptomatic cases, such as gastroenterological, cancer 
and rheumatoid arthritis. Children and pregnant women were excluded 
from participating in the study. Stability of RET-He, RBC-He, HB, mean cell 
volume (MCV) and mean cell haemoglobin (MCH) were evaluated to 
determine if there was significant shift in the result over 96 h and at varying 
temperature 40C, 200C and 300C. RET-He and RBC-He were also added to 
the haematological iron assessment in the follow up monitoring of 
haemochromatosis patients to evaluate their usefulness. 
 
 ii 
 
The serial measurement shows reasonable stability for MCH, HB, RET-He 
and RBC-He for up to 96 h. Elevated shift were recorded for MCV on all the 
samples in the same time frame. Receiver operating characteristic (ROC) 
analysis was used to obtain sensitivity and specificity of the biochemical and 
haematological iron indices measured in the study. Female patients were 
classified into ID using SF ≤ 20 ng/mL. The area under the curve (AUC) in this 
group were (SF = 0.99 versus RET-He and RBC-He = 0.72). RET-He has 
(sensitivity, 89.6% and specificity, 58.0%), and RBC-He, (sensitivity 88.6% 
and specificity 57.0%) in detecting ID. Female patients with IDA were 
classified using HB ≤ 11.5 g/dL. The AUC were (HB = 0.99; versus RET-He = 
0.87 and RBC-He = 0.86). RET-He has (sensitivity, 84.0% and specificity, 
72.0%) and RBC-He (sensitivity 82.0% and specificity 71.0%) versus HB 
(sensitivity, 100.0% and specificity, 99.9%) in detecting IDA. In male patients 
with ID, SF < 20 ng/mL was used for classification, AUC were (SF = 1.00 
versus RET-He = 0.78 and RBC-He = 0.79). RET-He has (sensitivity, 78.4% and 
specificity, 66.0%) and RBC-He (sensitivity 80.0% and specificity 61.2%), 
against SF (sensitivity, 100.0% and specificity, 100.0%) in detecting ID. In 
male patients with IDA, HB <13.5 g/dL was used for classification, AUC were 
(HB = 0.99 versus RET-He = 0.89 and RBC-He = 0.87). RET-He has (sensitivity, 
88.6% and specificity, 83.0%) and RBC-He (sensitivity 83.8% and specificity 
80.0%) in detecting IDA in male patients. Diagnostic plots were used to 
assess the ability of RET-He and RBC-He in comparison to other biochemical 
and haematological parameters, RET-He and RBC-He emerged as possible 
predictors of ID and IDA in inflammations and chronic diseases. The results 
of RET-He and RBC-He when measured with the other haematological 
parameters in the follow up treatment of haemochromatosis patients, 
shows 99% agreement with HB, MCV and MCH. 
 
In conclusion, the inclusion of RET-He and RBC-He into the iron studies 
investigation may improve the identification of ID and IDA in chronic 
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disease and inflammation, and can possibly detect changes in the cohort of 
cells with inadequate haemoglobinisation. Therefore, both indices hold 
promise as an alternative to biochemical iron studies especially, in patients 
with acute phase response and chronic diseases.  
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CHAPTER 1   Literature review  
1.0  Introduction 
Iron status is described as a continuum from iron deficiency with anaemia or 
iron deficiency without anaemia to normal iron status with varying levels of 
storage iron, and finally to iron overload which results in haemochromatosis 
which can consequently lead to severe organ damage if untreated (World 
Health Organisation, 2001, p.3). 
The World Health Organisation (WHO) is one of many organisations that has 
highlighted the seriousness of iron deficiency and anaemia caused as a result 
of its depletion. Iron deficiency (ID) is probably the most frequent nutritional 
deficiency in the world (Bohmer et al., 2003). More than two billion people, 
equivalent to over 30% of the world population suffer from the most serious 
type of ID with significant and obvious signs of iron deficiency anaemia (IDA) 
(Bohmer et al., 2003). ID was identified as one of the ten leading risk factors 
for disease, disability and death in the world, with a much greater impact 
than either vitamin A or zinc deficiency. The prevalence of IDA is believed to 
be around 2-5% amongst men and post-menopausal women in the 
developed world (World Health Organisation, 2001, p.3). 
Iron plays an important role in health and disease (Conrad, 1999). In fact 
Bryan (1931) indicated that documented therapeutic uses of iron dated back 
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as far as 1500 BC. However, it was not until 1872 that iron was recognised as 
a vital nutrient for animals (Boussingault, 1872). Iron is an essential trace 
element and the key component of many cellular enzymes, such as catalases, 
peroxidases, cytochromes, ribonucleic reductases, aconitases, and nitric 
oxide synthases, all of which are required for metabolic and oxidative 
processes intrinsic to life (Boldt, 1999; Conrad, 1999). These enzymes can be 
implicated in the development of a wide range of diseases, such as iron 
disorders, cancers, neurodegenerative diseases, and ageing (Conrad, 1999). 
Iron represents approximately 35 mg/kg and 45 mg/kg of body weight in 
adult women and men respectively (Bothwell et al., 1995). The average 
western diet contains 10-15 mg of iron, from which only 5-10% is absorbed 
(Bothwell et al., 1995).  
Before the twentieth century, most advances in the biochemical assessment 
of iron seemed to parallel, rather than complement the developments seen 
in haematology. Central to all of these are the processes involved in the 
absorption of iron, which detect and respond to the requirement in the body. 
The process is known as the physiology of iron. 
 
1.1  Physiology and functions of iron 
Iron incorporated in haemoglobin in red blood cell is required for the 
transport of oxygen by the blood to all organs in the body. It is essential for 
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growth, brain cell development, physical activity and capacity to work (Beard, 
2001). Iron is transported by haemoglobin (HB) in the blood, and when HB is 
rich in oxygen, it is red. When ID is present, there is less HB (World Health 
Organisation, 2004). Iron is involved in electron transport and has 
physiological functions which guide the availability of iron in the body. 
Therefore, too little iron can interfere with these vital functions and possible 
morbidity and mortality may be the outcome (Centre for Disease Control, 
1998).  
An adequate supply of iron is required for normal haemopoiesis (blood cell 
formation), which is important in the immune response system and helps 
white blood cells produce compounds necessary in fighting bacteria (Fairbank 
& Klee, 1999; Beard, 2001; World Health Organisation, 2004). 
In normal adults, 0.5-2 mg of iron is lost daily due to blood loss and the 
constant exfoliation of iron-containing epithelial cells that line the 
gastrointestinal and urinary tracts, skin and hair. To maintain homeostasis, 
the same amount of iron is required each day to replace the lost iron (Sharp 
et al., 2007). Excessive iron can lead to the formation of reactive radicals and 
can cause cell damage. This can also contribute to the development of 
numerous iron disorders, neurodegenerative diseases and possibly cancers 
(Sussman, 1992). In human cells, the expression of many key molecules that 
are involved in iron metabolism is controlled by the level of intracellular iron 
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via feedback mechanisms through gene expression at the post transcriptional 
level and specific mRNA-protein interactions in the cytoplasm (Haile, 1999).  
 
1.2  Dietary sources of iron  
Dietary iron exists in two forms, haem (found almost exclusively in meat) and 
non-haem (found in plants and animals). The main contributors to iron intake 
in the United Kingdom are fortified cereals, bread, meat products and 
vegetables. The average diet contains about 10-15 mg of iron daily. This is 
made available in the form of haem proteins, haemoglobin and myoglobin, 
the majority of which are derived from meat (Roach & Benyon, 2003). 
Previously, inorganic iron in the diet came from iron cooking utensils. In 
historic times, Justus von Lieberg, a Professor of Organic Chemistry at the 
University of Giessen, who carried out various experiments on animal 
physico-chemical systems, advocated the science of biochemistry. His view 
was that the minerals in the body came pre-formed as organic compounds 
derived from plant foods, and this view was widely accepted (Lieberg, 1842). 
Many other scientists in that era also propagated the views of Lieberg (Curtis, 
1906; Chittenden, 1907). However, Gustav von Bunge, Professor of 
Physiology at the University of Basle, who followed in Lieberg’s footsteps, 
heralded uncertainty over Lieberg’s view, he however, suggested that ‘the 
habitual consumption of foods poor in iron may lead to anaemia. He also said 
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that, ‘it is difficult to imagine a diet that would not contain the small amounts 
of the metal required daily’ (Bunge, 1902). Bunge later showed in further 
studies that some foods were low in iron, particularly human milk, and 
recognised the high level of iron in spinach, egg yolks, beef, apples and lentils 
which are required for consumption on a regular basis to prevent an 
individual from suffering from anaemia (Bunge, 1902). More surprisingly, he 
indicated that iron from haemoglobin in meat was poorly absorbed, which is 
in contrary to recent evidence that haem is rapidly absorbed from the 
gastrointestinal tract (Roach & Benyon, 2003).  
 
1.3  Absorption of iron 
The intestine serves as the major control for iron regulation. It controls the 
uptake of dietary iron across the membrane to the circulation. In the lumen, 
iron exists as ferrous and ferric iron salts. This happens because ferric iron 
becomes insoluble at pH ≥ 3 and ferric iron must be reduced by amino acids 
or sugars to be efficiently absorbed and most ferrous iron is soluble at pH 7 
(Conrad et al., 1999). Therefore, absorption of the ferrous iron salt is more 
efficiently processed than the ferric iron salts (Conrad et al., 1999). As most 
dietary iron exists in the form of ferric iron salt, its reduction becomes 
necessary for efficient absorption, and this can be achieved by the interaction 
of the intestinal enzyme mucosal ferrireductase (Ekmekcioglu et al., 1996). 
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Alternatively, the absorption of ferric iron may be processed in a less 
effective way by the mediation of the paraferritin pathway (Han et al., 1995). 
Any form of reduction in the activities of these enzymes will result in 
reduction of iron absorption, which may consequently lead to an iron 
disorder. 
The nutritional absorption of both haem and non-haem iron uptake occurs in 
the proximal small intestine, specifically in the duodenum and jejunum 
(Wood & Han, 1998). Enterocytes located on the intestinal villi are highly 
specialised and polarised absorptive cells which control the passage of 
dietary iron in the lumen and transfer into the body’s circulation (Wood & 
Han, 1998). The process undertaken before its transfer into the body’s 
circulation involves three cellular membrane barriers: iron absorption across 
the apical membrane, intracellular membrane and then into the circulation. 
This transfer process is facilitated by a divalent cation transporter known as 
“natural resistance-associated macrophage protein”, and it helps transport 
iron from the duodenum lumen into the cytoplasm of epithelial cells 
(Gruenheid et al., 1995). Haemoglobin iron from food is absorbed more 
efficiently from inorganic iron, the absorption of iron from myoglobin and 
haemoglobin differs distinctly from inorganic iron (Conrad et al., 1999). The 
first stage involved in the haem iron uptake involves the enzymatic digestion 
of haemoglobin iron in the lumen. The haem molecules then proceed into the 
absorptive cell as an intact metalloporphyrin. Following this, haem molecules 
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enter the cells via the haem mediated receptor-mediated internalisation 
process (Mills & Payne, 1995). Haem is degraded in the enterocytes by haem 
oxygenase to yield inorganic iron. Inorganic iron is either stored as ferritin or 
transported into the body’s circulation. Once this process has been 
completed by the enterocytes, iron that remains in the form of ferritin will be 
degraded with the senescent cells and excreted through the gastrointestinal 
tract. This process represents an important mechanism of iron loss (Mills & 
Payne, 1995). 
 
 
Figure 1.1:  Iron absorption, storage and transport pathway (Reproduced with 
permission from Andrews, N.C. (1999, pp. 1986-1995). 
 
Iron absorption by the enterocytes in the gastro duodenal junction is 
regulated in several ways (Figure 1.1). It can be modulated by the amount of 
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iron consumed in the diet, known as “dietary regulator” (Andrews, 1999). 
Also, following adequate consumption of iron in the diet and depending on 
the cellular absorptive ability, the enterocytes may resist further acquisition 
of iron, this process is known as “mucosal block” (Andrews, 1999). The 
second regulatory mechanism will sense the body stored iron levels rather 
than the dietary iron status, this mechanism is termed the “store regulator”. 
The store regulator can influence the uptake of iron by about two to three 
factors in iron-deficient conditions, and the final mechanism is known as 
“erythropoietic regulator”. This has a greater capacity to increase iron uptake 
in response to the requirement for erythropoiesis (Andrews, 1999).  
 
1.4  Iron metabolism 
An important issue of iron metabolism in man is that it is very conservative, 
because there is no controlled excretory mechanism. Iron is recycled to the 
extent that the movement of iron within its compartment is described as an 
iron cycle.  
Iron homeostasis is maintained by regulating its import, that is, during times 
of deficiency its uptake is stimulated, whilst under iron-rich conditions, 
uptake is suppressed to prevent toxicity (Smith et al., 1992). 
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The majority of total body iron (about 60-70%) is found in the haem 
compounds, especially in the form of haemoglobin and myoglobin, while the 
storage forms of iron, ferritin and haemosiderin, consist of about 30%, and 
only a minute amount (0.2%) is carried and bonded with a transport protein, 
transferrin (Brugnara, 2000). The production of two-three million red blood 
cells every second requires an adequate supply of iron, and iron moves freely 
from plasma to the marrow cells that have the capacity to make 
haemoglobin, this process allows the developing red cells to synthesise 
sufficient haemoglobin, so that they emerge into the bloodstream with 
intracellular haemoglobin as mature red cells (Conrad et al., 1999). This is a 
dynamic process that enables a total daily output of 6 g of haemoglobin from 
the marrow, as it is required for the production of erythroblasts (Brugnara, 
2000). Iron metabolism takes place in specialised tissues; the testes, 
intestines, placental and skeletal muscles, and high levels of iron are found in 
the liver, erythrocytes, brain and macrophages (Andrew et al., 1999). 
Iron uptake by the body is regulated by a peptide hormone known as 
hepcidin. When body stores of iron are high, the liver secretes hepcidin (Park 
et al., 2001). Hepcidin has been identified as the key regulator in systemic 
iron mobilisation. It was first identified in urine as a small bactericidal peptide 
(Krause et al., 2000; Park et al., 2001). Hepcidin is a 25-amino-acid molecule 
which is closely similar to the defensin antimicrobial peptides (Krause et al, 
2000; Park et al, 2001). It explains how iron release from absorptive 
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enterocytes and macrophages is controlled within the circuit. The first 
connection between hepcidin and iron metabolism was ascertained by 
Pidgeon et al., (2001). Hepcidin is noted to decrease iron absorption in the 
intestine and also block the export of ferroportin, which is responsible for 
iron efflux into the cells when required for erythropoiesis (Nemeth et al., 
2004).    
 
   
Figure 1.2:   Role of hepcidin in iron regulation (Reproduced by permission from Ganz & 
Nemeth, (2006, pp. G200). 
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Ferroportin is a transmembrane protein that serves as the sole cellular efflux 
channel for iron from the inside of a cell to the outside of it. It is found on the 
surface of the cells that transport and store iron including enterocytes, 
hepatocytes and macrophages. The efflux is regulated by the iron regulatory 
hormone hepcidin. The process involves internalisation and degradation of 
ferroportin, which is available on the cell surface of macrophages and 
enterocytes, and causes iron to become trapped within enterocytes, 
hepatocytes and macrophages leading to reduction in iron uptake. It has 
been identified during inflammation that the cytokine interleukin-6 alone can 
rapidly induce hepcidin production and result in corresponding 
hypoferraemia (Nemeth et al., 2004). The process of iron metabolism shows 
that excess intracellular iron can possibly lead to the formation and 
deposition of haemosiderin which can lead to cellular dysfunction and 
damage, also the consequence of excess iron intake is haemochromatosis 
(Gerlach et al., 1994). 
The biological importance of iron is in its chemistry, because it exists in both 
ferrous (Fe2+) and ferric (Fe3+) oxidation states, which means iron is capable 
of accepting and donating electrons, this oxidation-reduction reaction is 
known as Fenton reaction (Weissling-Ressnick, 1999). 
 
Fe3+ + O2
- → Fe2+ + O2;  Fe
2+ + H2O2 → Fe
3++ OH + OH-    (Eqn 1) 
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The reaction above (Eqn 1) is important for the biochemical functioning of 
iron especially in cellular metabolic processes. The deleterious effect of iron 
can be likened to its ability to produce reactive oxygen species within the 
Fenton reaction (McCord, 1998). The highly reactive oxygen species like the 
hydroxyl (OH-) and superoxide radicals (O2
-) are very toxic because of their 
ability to react with every molecule found in the living cells. This can result in 
DNA damage, impaired synthesis of proteins, membrane lipids, and 
sometimes altered cell proliferation (Smith et al., 1992; McCord, 1998). 
The process described above has led to suggestions that iron plays a role in 
carcinogenesis, the pathogenesis of atherosclerosis and neurodegenerative 
disorders such as Parkinson’s or Alzheimer’s disease (Jenner, 1991; Connor et 
al., 1992). Therefore, to reduce the effect of this toxicity using a highly 
sophisticated mechanism, molecules for the acquisition and transport of iron 
in soluble, non-toxic forms have evolved to meet cellular iron needs, and also 
to control homeostasis. Although the amount of iron extracted from the diet 
is small, regulation of intestinal absorption is critical because humans have no 
active physiological pathways for excretion. Duodenal crypt cells sense the 
iron need of the body by taking up iron from plasma transferrin at the 
basolateral surfaces and migration to the villus region. Therefore, iron levels 
are thought to be predetermined in the crypt cells and control the expression 
of iron transporters in the body as they mature into absorptive enterocytes 
lining the absorptive villi close to the gastrointestinal junction (Andrews et 
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al., 1999). Physiological iron loss from the body includes minute excretion 
from the bile, urine and daily loss through the gut and skin, which represent 
about 1 mg/day in adults (Andrews et al., 1999). Women experience 
additional iron loss through monthly menstrual bleeding and during 
pregnancy. The balance of red cell production and destruction maintains the 
HB level. When production fails to keep up with the destruction, either as a 
result of blood loss through disease or injury, or reduced dietary intake of 
iron, there will be a reduction in the HB level until it reaches an arbitrary level 
to indicate anaemia (negative iron balance).  
 
1.5  Factors influencing iron bioavailability 
There are numerous factors which affect iron absorption and bioavailability. 
The factors are age, iron status, species, dosage level and organic and 
inorganic nutrients. McCance & Widdowson (1937) proposed that efficiency 
of absorption was due primarily to the iron status of the animal. Bothwell et 
al. (1995) also indicated that the two most important factors influencing iron 
absorption were iron stores and rate of erythropoiesis. This substantiates the 
mucosal block theory that a human only absorbs what it needs or requires 
(Andrews, 1999). Increasing levels of dietary iron lead to higher total 
amounts absorbed and, because of its potential ability to cause deficiency or 
overload, iron status remains the most influential in determining its 
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absorption, and that is why it is very necessary to study iron status and 
deduce an improved way of assessing its levels in health and disease. 
 
1.6  Victorian era of anaemia 
From the 16th to the early 19th centuries, several interesting historic issues 
regarding the lack of iron in the body have been discussed. Anaemia, 
hypochromia, and lack of iron in the blood were first discussed in the 1830s 
by Hoefer, Popp, and Foedisch respectively (Fowler, 1936), and many workers 
continued to improve the understanding of this discovery. Several conditions 
were used to describe the clinical effects of ID in the medical literature, 
followed by the terminology anaemia meaning lack of blood or a decrease in 
red blood cells.  
In 1836, Ashwell defined chlorosis as a disease of the blood characterised by 
anaemia and lack of iron. Chlorosis, also called ‘green sickness’, morbus 
virgeneus, mal d’amour, is a fascinating disorder resulting in ID in adolescent 
girls between the ages of 14 and 17 years with gastrointestinal and menstrual 
disorders, and its prevalence peaked in the Victorian era (Patek & Heath, 
1936; Guggenheim, 1995). The term chlorosis was frequently used and 
adopted in medieval ages and then completely disappeared as a clinical 
entity before World War II (Hart, 2001). The hypothesis adopted to explain 
chlorosis compared the disease with the use of tight lacing of the body with 
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corsets or other materials worn by girls and women in the 16th century. The 
prevalence was so high during this period that scientists thought wearing 
these garments could have possibly compressed the liver, which is believed 
to have caused displacement of the abdominal organs, even though this must 
have resulted from other causes like reflux oesophagitis resulting in blood 
loss, other than mere compression (Hansen, 1931). In today’s terms, we do 
not regard even severely anaemic individuals as green. The nomenclature has 
changed. Most of the features associated with chlorosis are apparent in IDA. 
The picture of chlorosis was viewed as a combination of numerous factors 
relating to demands of growth and the onset of menstruation, inadequate 
diet and possibly lack of iron stores at birth as a consequence of ID in 
mothers. Patients who suffered from chlorosis responded very well when 
treated with iron replacement pills (Haden, 1938).  
Another form of ID which has been described after the demise of chlorosis is 
simple achlorhydric anaemia. Others referred to it as idiopathic or primary 
hypochromic anaemia (Witts, 1931; Wintrobe & Beebe, 1933). Like chlorosis, 
this type of anaemia mainly affected women, especially those with poor 
diets, menstrual problems and multiple pregnancies, and it occurs later in life 
around the ages of 40-50 years (Wintrobe & Beebe, 1933). Following some 
studies carried out, the pathogenesis of this condition has become clearer, 
and it was identical to what is known as IDA nowadays. Therefore, it is called 
chronic hypochromic anaemia. The clinical features include epithelial changes 
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seen in nails, tongues and achlorhydria. Patients suffering from chronic 
hypochromic anaemia were found to be responsive to iron therapy, although 
there were controversies concerning the dosage and preparation of iron that 
was required to treat the disease (Haden, 1938). 
 
1.7  Iron deficiency: physiological stages  
The physiological disorder of iron metabolism is related to an increased iron 
need during growth and developmental phases, while the pathological causes 
are as a result of loss of iron due to a serious or chronic medical condition, 
which also depends on a range of factors, such as age, co-morbidity, and 
concomitant therapies (Rockey & Cello, 1993). The overall understanding is 
that ID results from an imbalance of supply and demand for iron in the body, 
whereby the requirement versus rate of absorption is not met. Hence, 
patients with ID possibly have inadequate intake, impaired absorption, 
suppressed transport or iron losses as a result of reproductive age or chronic 
blood loss. Despite various established diagnostic protocols and guidelines, 
many patients suffering from ID still lack definitive aetiology, and this makes 
it difficult to establish and identify the condition more accurately (Rockey & 
Cello, 1993). ID is the most frequent cause of anaemia worldwide, affecting a 
large number of children and women, especially in developing countries 
(Nojilana, et al., 2007). It is also the only nutrient deficiency which is 
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prevalent in highly industrialised countries with the number currently 
standing at two billion people, over 30% of the world’s population (World 
Health Organisation, 2010). The fundamental aetiologies are a result of 
inadequate amounts of iron being consumed, and an excessive blood loss 
with disorders in its metabolism (Pollitt, 1993).  A wide range of physiological 
states including pregnancy and aging have also been implicated. This negative 
iron balance resulting in exhaustion of total body iron stores and diminishing 
SF ≤ 12 µg/L is always indicative of ID with or without anaemia (Goddard et 
al., 2000; Jolobe, 2000). The magnitude of the problem of ID and its effect on 
global health is well appreciated, especially by the people who have been 
working in the field of nutritional studies. It is quite obvious that clinical 
interests have focussed on early diagnosis of ID, to prevent patients from 
progressing to a more serious and acute disease stage. IDA still remains the 
most common treatable anaemia in the world, once the cause of the 
underlying anaemia is identified. Major fundamental progress has been 
introduced for physiologic and pathologic connections between iron 
metabolism and erythropoiesis, which include multiple genes and factors 
which regulate erythropoiesis (Orkin, 2000). ID without overt anaemia can 
result in neuropsychological effects and has been linked to delayed cognitive 
development in children and adolescents (Grantham-McGregor & Ani, 2001). 
This delay has been shown to respond to iron therapy (Sandstead, 2000).  
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The stage of development of ID is usually sequential. It spans over a long 
period of negative iron balance. As the body iron begins to fall, there is a 
characteristic pattern of events that results in three stages in which 
deficiency of iron is seen. The first stage is known as the iron depletion stage, 
which is also known as the pre-latent ID stage. For the majority of the time 
during this stage, even though there is iron depletion, the diagnosis using 
serum iron cannot be made as serum iron is not necessarily reduced due to 
the iron supply from storage molecules (Choi, 2003). Therefore, detection of 
ID at this stage would depend on the measurement of serum ferritin (SF). A 
low SF concentration is sensitive for appraising iron depletion when there is 
no inflammation. However, its use has limitations, because it can be elevated 
by any type of chronic inflammation. The use of biopsy techniques can be 
employed, but this method is invasive.  
The next stage of deficiency is known as latent ID. This is the stage where iron 
depletion is complete and storage has been exhausted. The HB level is mostly 
higher than the lower reference limit during this stage and the mean cell 
volume is usually normal. This stage presents a characteristic difficulty for 
clinicians to diagnose using haematological parameters alone. Therefore, 
some biochemical parameters are always requested. On most occasions 
decreased concentrations of ferritin and transferrin saturation are useful in 
the diagnosis, and an elevation of erythrocyte protoporphyrin have been 
utilised in the diagnosis (Heinrich, 1968; Verloop, 1970; Köller, et al., 1978). 
 19 
 
The final stage in the development of ID is the progression from the state of 
deficiency of iron to anaemia. This is the stage where the HB concentration 
falls below the lower limit of the reference interval, and is known as IDA. 
 
1.8  Features of iron deficiency 
The generic clinical features associated with ID include fatigue, lassitude, 
pallor, weakness or palpitation, decreased work performance and sometimes 
headaches (Davies et al., 1973).  The nature of these symptoms depends on 
the severity of the anaemia and the impact it has on quality of life (Cella, 
1998; Wood & Ronnenberg, 2006).  In childhood, measurable cognitive 
abnormalities may be observed (Pollitt, 1993). Another bizarre behavioural 
symptom that is peculiar to both children and adults is pica. Pica is 
characterised by the inappropriate ingestion of non-nutritive substances, 
although it may disappear following iron therapy (Moore & Sears, 1994). It is 
important to note that these symptoms are vague and may not necessarily 
provide adequate information for the diagnosis of ID in hospitalised patients 
(Elnicki et al., 1992). In general, the clinical symptoms of ID are somewhat 
non-specific, and are often difficult to attribute to anaemia. Findings common 
to anaemia may be present, and some individuals with ID may not even 
experience any symptoms. ID develops slowly in chronic blood loss and 
disorders in homeostatic mechanisms of iron (Frewin, 1997). As the clinical 
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manifestations of ID are usually unclear, most cases are mainly identified 
routinely by laboratory screening. High-risk groups, in which laboratory 
investigations have proved useful, include infants, children, adolescents and 
women between the ages of menarche and menopause (Dallman et al. 
1980). 
 
1.9  Iron deficiency anaemia 
Iron deficiency anaemia (IDA) may occur as a result of occult chronic blood 
loss from the gastrointestinal tract, and its evaluation is always a very critical 
and challenging strategy for an effective diagnosis to be achieved. This 
common clinical problem must be properly evaluated and dealt with.  It is 
understood that either acute or chronic blood loss is one of the numerous 
causes of IDA and both the upper and lower gastrointestinal tract may be the 
culprit of iron depletion (Peterson, 1989; Centre for Disease Control and 
Prevention, 2007). The examination of the colon has actually become a 
standard practice during investigation, and many clinicians would proceed to 
order colonoscopy or even barium-enema radiography regardless of signs 
and symptoms in the upper gastrointestinal tract. It has also been established 
that chronic colonic blood loss could be attributed to mass lesions (Peterson, 
1989; Ahlquist, 1991). The symptoms that could be linked to the upper or 
lower gastrointestinal tract were traced to the presence of lesions in the 
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esophagogastroduodenoscopy or colonoscopy. Cases of cancer, gastric ulcer, 
duodenal ulcer, carcinoma, erotive gastritis and possible coeliac disease 
would represent conditions where the gastrointestinal tract should be 
investigated for possible bleeding.  
 
1.10  Anaemia of chronic disorders 
Anaemia of chronic disorders (ACD) is considered the second most prevalent 
type of anaemia caused by ID. This type of anaemia is seen in patients with 
acute or chronic immune activation, inflammatory or neoplastic diseases. It 
has some features that may be similar to IDA, and is also known as anaemia 
of inflammation (Weiss, 2002; Means, 2003). ACD is immune driven, and is 
characterized by inadequate production of erythropoietin, and causes an 
increase in the production of inflammatory cytokines (Means, 1995). This 
process will in turn increase the concentration of C-reactive protein (CRP) in 
the serum (Spivak, 2000). Even though the pathophysiology may not be fully 
understood, it is believed that the condition probably evolved as a cytokine-
mediated defence against microbial pathogens leading to changes in iron 
homeostasis. This process ultimately leads to withholding of iron from 
microbes and from the erythroid precursors and the resultant effect is the 
subsequent limitation of the availability of iron for erythroid progenitor cells, 
and iron-restricted erythropoiesis (Jurado, 1997; Andrews, 1999). 
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Erythropoiesis can be affected by disease underlying anaemia of chronic 
disease by the infiltration of tumour cells into the bone marrow or by 
microorganisms, as seen in cases of human immunodeficiency virus, 
infection, malaria and hepatitis C (Stenvinkel, 2001). In ACD, like IDA, 
functional ID is the limiting factor of erythrocyte haemoglobinisation. This 
process will in turn lead to a reduction in erythrocyte and reticulocyte 
haemoglobin content, and the characteristic feature is the occurrence of 
hypoferraemia in the presence of reticulo-endothelial iron stores. Otherwise 
the supply of iron in IDA depends on the amount of iron stores, whereas in 
ACD, the supply relies on the rate of mobilisation. The consequence of this 
process is that, in ACD, functional ID may occur, even in the presence of 
adequate stores, when iron release is impaired, because iron is simply 
unavailable for delivery to the bone marrow, and thus erythropoiesis is 
compromised, thereby leading to anaemia (Fillet et al., 1989).  
ACD is very common, and can be taken to be more common than any other 
type of anaemia except in cases where blood loss has resulted in iron 
deficiency (Means, 1999). It is without doubt that higher percentages of 
hospital patients will have ACD, and many studies have confirmed this fact. 
Cash and Sears, (1989) evaluated the anaemic patients admitted to a busy 
hospital over a period of 2 months. Patients with bleeding, malignancies and 
bleeding disorders were excluded from the study. It was found that 52% of 
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the total study population had ACD, using the standard laboratory diagnostic 
criteria.  
Considering the types of anaemia and the extent to which they can cause 
damage if untreated, Brugnara et al., (1999) indicated that early recognition 
of subclinical ID is necessary to prevent systemic complications of the 
disease. Also, the recognition of IDA caused by lack of iron, malabsoption and 
bleeding should be identified, as these conditions do respond promptly to 
therapy (Ferguson et al., 1992). Although, it is not uncommon to see patients 
with certain inflammatory conditions, like inflammatory bowel disease, 
present with both ACD and IDA, in this group of patients the IDA is usually 
secondary to intestinal blood loss, and the diagnosis may point to 
inflammation rather than truly reflect the actual poor iron status (Weiss & 
Goodnough, 2005). 
 
1.11  Haemochromatosis 
Haemochromatosis (or HFE-related hereditary haemochromatosis) is simply 
described as iron overload with the presence or absence of tissue injury to 
the organs involved, manifested by cellular damage and fibrosis (Madra et al., 
1996). Patients with iron overload absorb and store more iron than normal 
individuals. They continue to absorb more excessively even when they are 
overloaded. The excess iron is stored in the form of ferritin and 
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haemosiderin. These compounds are thought to be non toxic. However, iron 
released from storage sites can react with hydrogen peroxides to result in 
highly reactive oxygen species such as hydroxyl radicals. These can cause 
damage to proteins, nucleic acid and mitochondria (Madra et al., 1996). 
Some investigators considered haemochromatosis to be an inheritable 
disorder (McDonald, 1965; Saadi & Feingold 1974), and further investigation 
conducted over three decades ago corroborated the initial suggestion that 
haemochromatosis was transmitted as an HLA-linked, autosomal recessive 
disorder (Saadi & Feingold 1974). This was due to an inborn error of iron 
absorption. Although, the exact mechanism is unknown, it is believed that 
nearly 10% of the white Northern European origins are carriers of the gene 
indicating hereditary haemochromatosis. The prevalence indicates between 
three and five people out of a thousand are homozygous.  
The gene responsible for hereditary haemochromatosis is known as HFE 
(High iron Fe). The protein product of the HFE gene is a 343-residue type 1 
glycoprotein, which almost resembles the MHC class I protein in structure. 
Although changes in iron status appear to have little effect on the expression 
of HFE, the expression of the HFE gene is believed to participate in the 
metabolism of iron (Ganz & Nemeth, 2006). The potential linkage between 
the HFE gene product and cellular iron metabolism was discovered with the 
HFE protein forming a complex with the transferrin receptor (Feder et al., 
1996).   
 25 
 
Two classic mutations associated with HFE are C282Y and H63D. The most 
common form of hereditary haemochromatosis is a G-to-A transition at 
nucleotide 845, which is indicated by (G845A). G845A results in a cysteine 
substitution at amino acid position 282, hence its designation as C282Y 
(Olynyk et al., 2008). Some haemochromatosis patients also have an E-to-G 
transversion at nucleotide position 187 (C187G), this mutation is recognised 
as H63D (Olynyk et al., 2008). H63D substitutes an aspartic acid for histidine 
and has an allele frequency of about 16% in the European population. H63D 
has been claimed to have little effect when inherited alone. However, it 
would contribute to the disease process when inherited with C282Y (Ganz & 
Nemeth, 2006). 
HFE is thought to bind the transferrin receptor and subsequently influence 
the binding of transferrin and iron (Tf-Fe) intracellular delivery. HFE can 
indirectly influence the iron status of a cell population in vivo by modulating  
hepcidin expression (Figure 1.1). Some workers have shown that loss of HFE 
is associated with reduced expression of hepcidin, resulting in increased 
ferroportin-mediated iron efflux from duodenal enterocytes (Feder et al., 
1996; Frazer et al., 2001; Ganz & Nemeth, 2006). This is an indication that 
HFE has a role to play in iron overload. 
In patients with haemochromatosis, it is necessary to establish a diagnosis as 
soon as possible because death can occur within few years if untreated. 
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Treatment is by simple phlebotomy, removal of blood once or twice a week 
until about 50 L of blood has been removed. 
Routine screening of haemochromatosis involves the assessment of iron 
status. The initial screening should include the measurement of serum iron, 
TIBC, TSAT and SF. If TSAT is greater than 60%, further investigations should 
be considered to diagnose haemochromatosis (Witte et al., 1996). Decreased 
transferrin synthesis may be associated with liver dysfunction, and 
consequently result in an increased level of TSAT. This has been linked to 
excessive alcohol consumption in some individuals (Tavill, 2001). Transferrin 
is a negative acute phase reactant, and may be decreased in inflammation. 
Also, SF is an acute phase protein which may be elevated in inflammation and 
malignancies. Therefore, the interpretation of SF in the diagnosis of 
haemochromatosis should take into account all the confounding factors in 
addition to TSAT.  
Some workers have also found that the use of SF and TSAT together have 
good sensitivity and specificity of 0.85-0.90 and a positive predictive ability of 
0.65 (Witte et al., 1996; Bassett et al., 1989). Individuals who have repeatedly 
higher TSAT, in addition to an elevated SF concentration, should be 
requested to undergo HFE genotyping. The diagnosis of hereditary 
haemochromatosis is confirmed if the haemochromatosis associated 
genotype (C282YC282Y or C282Y/H63D) is present. This study will evaluate 
the haemoglobinisation indices and compare with other haematological 
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parameters to determine their usefulness in the diagnosis and management 
of haemochromatosis patients. 
 
1.12  Assessing iron status 
Various attempts to arrive at a single assay that could accurately reflect iron 
status have failed. This is because the iron compartments of the body behave 
independently of one another and may not reflect the true behaviour of the 
biological conditions in the body at all times. This has caused irreparable 
damage to the individual patient, even in acutely anaemic patients, where 
one would expect that a simple measurement of HB would identify low iron 
status. It has on many occasions proved inaccurate, due to its low sensitivity 
and specificity (Cook, 2003). Even the determination of serum iron 
concentration has been made obsolete as a result of various biological 
rhythms. Therefore, a host of haematological and biochemical assays are 
used to identify the various stages of iron depletion that ultimately result in 
IDA. 
Traditionally, scientists have used various biochemical and haematological 
tests to diagnose the presence or absence of ID (Worwood, 1997). The 
conventional iron storage parameter is SF (Briggs et al., 2001) and its use has 
been criticised by numerous workers because it is an acute phase responder 
and may be inaccurate in cases where inflammation is present (Briggs et al., 
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2001; Thomas & Thomas, 2002). Even though the examination of stained 
bone marrow for haemosiderin is considered the ‘gold standard’ method, the 
technique is invasive and has been deemed unsuitable for the purpose of 
screening, especially in a large population setting (Hansen, 1983; Cook, 
1994). Therefore, the non-invasive approach has been used for the 
evaluation of iron status. The biochemical indicators used include serum iron, 
SF, transferrin saturation, sTfR, and the ratio of these parameters have been 
studied in various pathological conditions to establish their usefulness. The 
haematological indices used are HB, HCT, MCV, MCH, abnormal RET-He and 
RBC-He indices have the ability to identify hypochromic or microcytic cells. 
The use of zinc protoporphyrin (ZPP) has also provided valuable indication for 
the diagnosis of ID and is still being used in some laboratories (Worwood, 
1997). However, many of the parameters listed have their strengths and 
weaknesses. In most cases, the weaknesses have overpowered the diagnostic 
ability which makes them unreliable (Wish, 2006). Although some of these 
markers, including the RET-He and percentage hypochromic red cells show 
promise for identifying ID (Cullen et al., 1999; Chuang et al., 2003), none yet 
has been established to have the combination of accuracy, ease of use, cost-
effectiveness, and widespread availability of the traditional tests. 
Given these factors, the aim of this study was to investigate the diagnostic 
potential of new cytometric indices (reticulocyte haemoglobin content and 
erythrocyte haemoglobin content) in conjunction with the other 
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haematological indices, in assessing disturbances to iron metabolism. The 
focus of the remainder of this literature review will be to explore the 
available literature in describing these parameters of ID.                                                                                                                                                                                         
 
1.12.1  Haemoglobin 
HB is the protein contained in red blood cells. It is responsible for the 
transport of oxygen to the tissues. Therefore, HB levels must be sufficiently 
maintained in the body to allow adequate tissue oxygenation.  
HB determination is the most widely used screening method for ID. In 
general, the international agreement is that HB should serve as the key 
indicator of anaemia (International Nutritional Anaemia Consultative Group, 
1977; World Health Organisation, 2010). HB in whole blood is expressed in 
grams per decilitres (g/dL). The normal range for males, is 14-18 g/dL, and 
females, is 12-16 g/dL (World Health Organisation, 2001). HB is measured by 
an automated cell counter from a tube of well-mixed ethylene diamine 
tetraacetic acid (EDTA) anti-coagulated blood. The principle involves the 
conversion of all forms of haemoglobin to the coloured protein 
cyanomethaemoglobin, the product of which is measured colorimetrically.                                              
The World Health Organisation (WHO) defines anaemia as a haemoglobin 
concentration below the established cut-off levels. That is, below 13 g/dL in 
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men, below 12 g/dL in non-pregnant women and below 11 g/dL in pregnant 
women (World Health Organisation, 2001). HB concentrations are reduced to 
below-optimal levels in ID and, when the level falls below two standard 
deviations of the distribution mean in a normal population of the same 
gender and age, IDA is believed to be present. However, the definition of 
anaemia as suggested by the WHO expert committee and various other 
sources has been repeatedly decried, and attempts to propose a new lower 
limit of normal haemoglobin based on individual age, race and sex have been 
put forward (Cook et al., 2003; Beutler & Waalen, 2006). Artz and Dong 
(2008) challenged the suggestion of Patel et al., (2007) when they indicated 
that “alternative criteria are warranted” for defining anaemia in black 
individuals. The reason for the criticism was because the authors believed 
there could be serious consequences in lowering the threshold of the 
haemoglobin concentration in determining if a black individual is truly 
anaemic or iron deficient (Artz & Dong, 2008). The WHO criteria for using 
haemoglobin were established in 1968, and the threshold was believed to be 
based on a study involving a small population. Other findings over the last 
forty years based on large populations have highlighted the differences seen 
in haemoglobin concentrations in black, whites, young and old (Perry et al., 
1992; Beutler & West, 2005; Beutler & Waalen, 2006). The survey carried out 
by the US National Health and Nutrition Examination Survey (NHANES III, 
1988-1994) (US Department of Health and Human Services, 1994), and the 
Scripps-Kaiser database were based on large data sets, and the outcome of 
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these have been used to propose a new definition for anaemia. The National 
Health and Nutrition Examination Survey assessed a national population of 
33,994 persons aged two months and older and seventy-seven percent of the 
people involved in the survey had their haemoglobin measured (Hollowell et 
al., 2005). The Scripps-Kaiser data also included the laboratory results of 
41,038 adults (Beutler et al., 2002). The outcome of the two surveys predicts 
that more people would be classified as anaemic if the new haemoglobin 
obtained were to be adopted, even though it is closely related to those 
established by the WHO over forty years ago. Therefore, the WHO 
haemoglobin values still retain their approval in most laboratories and clinical 
settings today. However, based on the controversies surrounding the cut-off 
points of HB in its use for the definitive diagnosis of anaemia, it is right to say 
that HB is used for screening purposes only, because of its limitations, the 
complex relationship with health outcomes and to prevent misdiagnosis and 
misclassification of anaemia as a result of its low sensitivity and specificity 
(Cook, 2003). For example, in latent iron deficiency, a condition where even 
though the iron stores may have become depleted, the haemoglobin level 
will remain higher than the lower limit of normal (Verloop, 1970). The 
diagnostic criteria used for identifying ID vary between different studies and 
populations. Therefore, the interpretation of HB values becomes the 
responsibility of the ordering clinicians.  
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1.12.2  Ferritin: merits and demerits as a marker of iron stores 
Ferritin is an iron-binding protein. It has been described as a ubiquitous 
protein with an iron core within a 24-polymer globular protein which is made 
up of heart and liver subunits, with molecular masses of 21 kDa and 19 kDa 
respectively (Harrison & Arosio, 1996). The cellular or tissue ferritin exists in 
two subunits as a polymer of heavier, more acidic H subunits and lighter, 
more basic L subunits (Cook, 1982; Theil, 1998). It is a spherical molecule 
consisting of an apoferritin shell and a ferric oxyhydroxide (FEOOH) 
crystalline core. The storage capacity of this protein shell may be up to 4500 
molecules of iron, but is usually 2000 or fewer (Theil, 1998). In most cells, the 
source of stored intracellular iron is ferritin, and it is available in nearly all 
cells of the body. Ferritin is important detoxifying machinery produced 
intracellularly in response to an increase in iron content, to prevent free iron 
from forming reactive oxygen species. The synthesis of ferritin is influenced 
by the available iron, whereas in ID, ferritin synthesis is diminished. The 
release of iron from ferritin is probably non enzymatic, and may involve 
reduction by reduced flavin mononucleotide or other reducing substances. 
The released Fe2+ leaves the crystal and diffuses out through a pore in the 
ferritin shell, hence the oxidation and reduction takes place rapidly (Torti & 
Torti, 2002). Ferritin is a very effective iron trap and also a readily available 
source of iron for metabolic purposes.  
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There is convincing evidence to suggest that serum ferritin concentrations 
are positively correlated with body iron stores, and it simply remains the best 
indicator of iron stores (Harrison & Arosio, 1996). Bates (1980) described 
serum ferritin as a sensitive and reliable measurement for the investigation 
of ID at an early stage. In the World Health Organisation and the Centre for 
Disease Control consultative group report in 2004, serum ferritin was chosen 
to be the best parameter for analysing the prevalence of iron deficiency in a 
population unless inflammation has taken over (World Health Organisation, 
2004). It is also known as an acute phase protein, which can act as an 
indicator of inflammatory disease in malignancy. Elevated levels are also 
often seen in conditions such as hyperthyroidism, hepatocellular disease and 
cancer of the liver and pancreas. This is also seen during infection, where 
serum iron concentrations decrease opposite to elevated serum ferritin 
concentration (Lorrier et al, 1985), indicating that serum ferritin suppresses 
bacterial growth by segregation of iron from bacteria (Lipinski et al., 1991). 
Although the mechanism for its elevation in the solid tumour has not been 
fully elucidated, cytokines such as Tumour Necrosis Factor - α (TNF-α) and 
Interleukin - 6 (IL6) induce the H chain of ferritin structure. This suggests that 
the pathway related to inflammation is affected (Harrison & Arosio, 1996). 
However, the use of SF in the diagnosis of ID has been widely criticised, and 
many researchers have classed it as unreliable. This is because an 
inflammatory response triggers the release of the acute-phase reactant, and 
ferritin is therefore falsely elevated in patients with ID. The SF concentration 
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is frequently found to be elevated in relative proportion to iron stores. 
Various approaches have been suggested on how to utilise and interpret SF 
as an indicator of iron status. Some recommended measurement of SF with 
either the erythrocyte sedimentation rate and or CRP (Mast et al. 1998). The 
gender differences (normally lower in women) have also been discussed as 
an issue when evaluating its utility in the diagnosis of ID (Mast et al., 1998). 
However, an important finding in the report of the joint WHO/Centre for 
Disease Control and Prevention consultative group on assessing the iron 
status of populations suggests that a review of data should be carried out to 
examine the alternative approaches, by using one or two acute phase 
proteins, either jointly with serum ferritin or as a standalone index to address 
the controversies (World Health Organisation, 2004). 
 
1.12.3 Serum iron, total iron binding capacity and transferrin 
saturation 
ID results in a reduction in serum iron levels, an elevation in TIBC levels, and a 
net reduction in transferrin saturation. However, the diurnal fluctuations, 
diet and negative acute phase reaction have serious implications on the 
reliability of these parameters. There is marked overlap in these indices 
between normal and iron-deficient individuals. Normal or high serum iron 
may be seen in patients with ID. Concentrations can also decrease in late 
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afternoon or evening and then peak in the morning. The concentration of 
serum iron decreases when an acute phase response sets in, even in the 
absence of ID. The overlap diminishes the usefulness of indices in 
determining if an individual is iron deficient. 
TIBC represents the amount of ferrous iron (Fe2+) that can bind to transferrin 
in the blood (Fairbanks, 1999). TIBC is indirectly deduced from the 
measurement of the unsaturated iron binding capacity (UIBC). TIBC is 
increased in IDA, while a decreased value is seen in ACD. 
 
Transferrin saturation (TSAT) is calculated using the following equation. 
TSAT % = Serum iron concentration x 100                  (Eqn 2) 
TIBC 
 
TSAT still remains a very useful index in the diagnosis of haemochromatosis. 
TSAT < 15% indicates ID (Skikne, 1994), while TSAT > 55% may be indicative of 
iron overload. According to Professor Gleeson (personal communication, July 
12, 2003) the recommendation is that TSAT > 50% in women and 55% in men 
should be followed by haemochromatosis genetic screening as it can be used 
to identify patients at risk of iron overload. 
 
 36 
 
1.12.4  Zinc protoporphyrin  
Zinc protoporphyrin (ZPP) is a metabolic intermediate that is produced in 
trace amounts during haem biosynthesis. This occurs following the 
incorporation of a zinc ion instead of a ferrous ion to form protoporphyrin IX, 
a precursor of haem (Labbe, 1999). The terminal pathway in haem synthesis 
is that iron is chelated by protoporphyrin. The reaction is enhanced by 
ferrochelatase, an enzyme that is bound to the mitochondrial membrane 
(Lange et al., 1999). The transfer of iron and zinc is tightly regulated, and 
both iron and zinc can compete for the metal binding sites on the 
ferrochelatase so that, when Fe2+ becomes suboptimal, Zn2+ is partially 
substituted (Lange et al., 1999; Outten & O’Halloran, 2001). This process 
results in increased ZPP formation (Labbe, 1999).  Therefore in iron 
deficiency, ZPP is produced instead of haem, leading to an increased 
concentration. ZPP may be an indirect marker of inflammation as it will 
increase due to iron sequestration. Impaired iron utilisation is a common 
occurrence in ACD and will lead to an increased ZPP (Hastka et al., 1996). 
Various workers have been studying ZPP since the 1930s. Van Den Bergh and 
Grotepass (1933) identified metal free protoporphyrin as contained in food. 
Following this discovery, other workers supported the evidence that truly 
protoporphyrin is responsible for the fluorocytes found in the circulating 
erythrocytes (Labbe, 1977). The presence of ZPP in the erythrocytes resulted 
in its deposition in the spleen and liver, therefore, when the aged 
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erythrocytes are sequestered, and the haem and ZPP are released, they 
become bound to the haem oxygenase, leading to slower degradation of 
haem (Maines, 1981).  
Dagg et al., (1966) were the first to highlight the fact that erythrocyte 
protoporphyrin could be used as an indicator of ID. The interest later grew 
and the effort to identify protophophyrin compounds with the use of 
fluorescence technology was introduced by Lamola & Yamane in 1974. Since 
this discovery, many workers have been able to demonstrate that the 
presence of ZPP in circulating erythrocytes was linked to exposure to lead 
(Lamola, 1974). 
The potential role of ZPP levels in ID diagnosis have been explained by Hastka 
et al., (1992) and some other previous workers (Crowell et al., 2006). They 
reported significant correlations between ZPP and ID. Elevated ZPP levels are 
an indication of iron-deficient erythropoiesis and, in a normal person without 
ID, ZPP is demonstrated to be < 60 µmol/mol haem. In their study, Mei et al., 
(2003) showed that erythrocyte protoporphyrin is a better screening 
parameter for ID than haemoglobin, and believed ZPP to have equal 
sensitivity and specificity with that of HB for identifying ID. Studies have 
shown that a slight shift from iron to zinc during haem biosynthesis will have 
a huge impact on the ZPP/H ratio in circulating erythrocytes and reticulocytes 
(Labbe, 1977). Due to the fluorescent technology employed in the 
measurement of ZPP, it is readily detectable as iron deficiency, even in its 
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lowest amount when present in the circulating erythrocyte, even before a 
lower level of HB is detected. This demonstrates that changes in ZPP are 
remarkably important in the diagnosis of ID (Brugnara et al., 1999). The 
World Health Organisation/Centre for Disease Controls (2004) report also 
suggests that meta-analysis of data should be looked at to examine the 
threshold of ZPP as an indicator of iron status. Seven years after, most of 
these recommendations have not been met. 
 
1.12.5  Transferrin receptor 
The transferrin receptor is a transmembrane protein whose function is to 
mediate the cellular uptake of iron from transferrin, a plasma protein which 
helps to transport iron in the circulation (Beguin, 2003). The expression of 
transferrin receptors by cells is proportional to iron requirements, especially 
for erythropoietic activity (Beguin, 2003). The process of uptake involves the 
binding of transferrin to the transferrin receptor. It is believed that the 
transferrin receptor does not directly interact with iron, but it is involved in 
iron acquisition by most cells, and part of a complex system that has evolved 
to control iron uptake and storage (Ponka et al., 1998). 
Jandl et al., (1956) were the first to suggest the existence of specific 
receptors for transferrin on the reticulocyte membrane, but it was not until 
the 1970s when several laboratories carried out further work and were able 
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to isolate the transferrin receptor from reticulocyte membranes, and 
subsequently from placenta and cultured cell lines (Hu & Aisen, 1978; Witt & 
Woodworth, 1978; Enns & Sussman, 1981). 
The human form of the transferrin receptor was first identified and 
characterised by Trowbridge and Omary in 1981. It consists of two identical 
transmembrane sub-units, with a molecular weight of 84,910 Da, containing 
760 amino acid residues, which are joined by two disulphide bonds at 
cysteine 89 and 98 (McClelland et al., 1984). 
Another determinant of iron status that has recently joined other 
biochemical ID diagnostic profile is the measurement of soluble transferrin 
receptors (sTfR). This parameter is typically reserved to distinguish between 
IDA and ACD, where ACD is associated with chronic inflammation and 
neoplasia (Rimon et al., 2002). The findings of the study conducted by Chua 
et al., (1999) in the investigation of the role of sTfR in ID and ACD in the 
elderly population concluded that there is possibility that cases of ID and IDA 
could be missed as a result of complexities of clinical conditions and 
inflammation. The sTfR test is based on the fact that erythroblasts in the 
bone marrow will increase the presentation of membrane transferrin 
receptor in cases of ID. The concentration of circulating sTfR correlates with 
the total receptor content of the cells (Cook, 1999). 
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The sTfR level remains unchanged in ACD, which is the reason why some 
workers have approved its uniqueness in distinguishing between iron 
deficiency as a result of various pathological conditions or inflammation from 
every other type of IDA (Ferguson, 1992). Elevated sTfR occurs earlier in 
functional iron deficiency, even sooner than the changes observed in free 
erythrocyte protoporphyrin or mean cell volume (MCV) (Cook & Skikne, 
1989; Punnonen & Irjamaki, 1997).  
In the study performed by Dimonte et al., (2002), they investigated the use of 
sTfR in assessing ID without anaemia in a group of patients who donated 
preoperative autologous blood. The findings showed sTfR to be a reliable and 
sensitive marker in the detection of ID (Dimonte et al., 2002). Another 
important related finding by Flesland et al., (2004), demonstrated sTfR as a 
valuable assay, and argued it could be better than ferritin in the diagnosis 
and prevention of ID in blood donors.  
The sTfR concentrations are determined by an immunoassay technique. This 
technique provides an alternative to the very cumbersome ferrokinetic 
studies that were previously used. In contrast to SF, sTfR levels are not 
elevated in patients with acute infections, including hepatitis, chronic liver 
disease and other conditions with chronic diseases, except where there is a 
co-existing ID (Ferguson, 1992). A reduced level of sTfR is observed in aplastic 
anaemia and renal cases when erythroid cell mass is reduced and in 
hyperproliferative states (Worwood, 2002). The shortfall of the sTfR assay is 
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that it lacks standardisation. Even though there are several commercial 
assays available, there is no common reference material available for its 
validation (Brugnara, 2003). 
 
1.12.6  New diagnostic dimension in the investigation of iron status 
It is clearly understood that iron balance is controlled by the rate of 
erythropoiesis and the size of the iron stores. This indicates that, in IDA, the 
supply of iron depends on the iron stores, whereas in FID, the supply depends 
greatly on the rate of mobilisation of iron. The production of 2-3 million red 
blood cells every second requires an adequate supply of iron which will allow 
the developing red cells to synthesize sufficient haemoglobin (Fillet et al., 
1989). Therefore, FID is defined as an imbalance between the iron required 
for erythropoiesis and the iron supply, which is not maintained at a sufficient 
rate to allow normal haemoglobinisation of red cells and the reticulocyte, 
even though there is an adequate body iron store (Frewin et al., 1997; Ponka 
& Lok, 1999).  This situation will lead to reduced reticulocyte haemoglobin 
content (RET-He) and red blood cell haemoglobin content (RBC-He), and this 
scenario is typically seen in patients with ACD (Fillet et al., 1989, Thomas & 
Thomas, 2002).  
The uncomplicated cases of ID can be diagnosed using the traditional 
haematological and biochemical markers to a certain extent and have been 
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described within this literature review. However, in complicated cases, the 
results of these traditional parameters may not be helpful. Even when the 
clinical manifestations are subtle, the identification of deficiency is still a 
worthwhile exercise, especially in the monitoring of treatment.  
The complicated case mentioned here is FID in acute or inflammatory 
conditions, because most patients go on to develop chronic anaemia. These 
types of anaemia pose a huge challenge to scientists and physicians when the 
goal is to diagnose and then initiate treatment.  
 
1.12.7  Reticulocyte haemoglobin and red cell haemoglobin content  
Reticulocyte haemoglobin (RET-He) and red blood cell haemoglobin content 
(RBC-He) have been known for nearly a decade. The parameters have 
acquired great clinical interest and importance in the assessment of FID. This 
is because the reticulocyte is the earliest form of erythrocyte released from 
the bone marrow into the peripheral blood. Reticulocytes actively produce 
haemoglobin, where the matured red blood cells do not. They circulate for 
18-36 h prior to maturation. Therefore, the haemoglobin concentration is 
measured in the reticulocyte, because they represent a real-time and direct 
determination of the current status of erythropoiesis and indicate the 
amount of iron contained in the red cell precursors (Brugnara et al., 1999; 
Brugnara, 2000; Thomas & Thomas, 2002).  
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The use of haematological parameters to identify FID was originally described 
by MacDougal (1992). He proposed that patients with FID could be identified 
by the use of % hypochromic red blood cells which was uniquely available on 
the Bayer H* haematology analyser at the time. The measurement of this 
index gained massive popularity amongst the renal physicians within Europe 
and the United Kingdom at that time and, shortly after that, literature began 
to present those parameters that measure the characteristics of the 
reticulocyte. The prospective indicator explored in many of those studies was 
the use of CHr, which was also unique on Bayer (H*3 and ADVIA). CHr is 
known as the mean value derived from the haemoglobin content of an 
individual reticulocyte, which is measured by the light scatter in the Bayer 
instrument.  
Until recently, the most widely studied reticulocyte indices were reticulocyte 
haemoglobin content (CHr) and the portion of hypochromic red cells 
(%HYPO) which were restricted to the Bayer ADVIA 120. However, with the 
introduction of Sysmex XE2100TM ten years ago, two groups (Briggs et al., 
2001; Thomas & Thomas, 2003) investigated the potential benefits of 
identifying FID using reticulocyte haemoglobin content (RET-He). The findings 
were that RET-Y provided good correlation to CHr, sTfR and % hypochromic 
red cells, and that RET-He could be an acceptable parameter for indicating 
FID. They also suggest the parameter may be substituted for CHr in patient 
management (Buttarello et al., 2004). Luo et al., (2007) also compared the 
 44 
 
diagnostic efficacy of CHr to other markers of ID in Chinese premenopausal 
women. They recommended further studies to determine whether CHr 
should be the preferred screening tool in the early detection of ID in a larger 
and unselected population of premenopausal women and children. 
The Sysmex XE-2100 (Sysmex, Kobe, Japan) is a discrete automated 
haematological analyser which utilises new technology to improve the quality 
of cell analysis, including red cell counts, immature granulocyte count and an 
optical fluorescent platelet count in situations where an impedance count is 
unreliable (Briggs et al. 2001). It uses automated fluorescent cytometry with 
the aid of polymethine dye to measure reticulocyte haemoglobin equivalent. 
RET-Y and RBC-Y values are generated from the reticulocyte channel of the 
Sysmex-XE2100 analyzer using the same forward scatter and fluorescence 
technologies that provide reticulocyte counts and maturation parameters 
(Brugnara, 2000). RET-Y is the forward scatter of fluorescence-labelled 
reticulocyte haemoglobin equivalent (RET-He), and RBC-Y represents the 
forward scatter of fluorescent-labelled erythrocytes which can be 
represented as RBC-He. RBC-Y and RET-Y indices are determined in a manner 
that is technically different from those on the Bayer Advia 120 analyzer. 
Therefore, they consequently require investigation to determine how much 
information they can provide to accurately diagnose and monitor the 
treatment of ID. This study is concerned with investigating these parameters 
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(RET-He and RBC-He), either as stand alone or in conjunction with other 
markers of iron that have been previously described. 
A number of studies have been conducted, but not in a similar patient 
population as proposed here. The majority of the studies already carried out 
focussed on renal patients undergoing haemodialysis. Two studies examined 
the clinical utility of the reticulocyte index (CHr), as measured on the Bayer 
Advia 120 and 2120, with comparison to other markers of ID. The optimal 
CHr concentration cut-off values for the diagnosis of ID differed slightly at 
26.0 and 27.5 pg in both studies (Brugnara, et al., 1999; Ullrich et al., 2005).  
In a number of clinical studies, CHr has proven to be useful in differentiating 
anaemia and, in monitoring erythropoietin therapy in renal patients 
undergoing dialysis, the sensitivity was good for detecting relative ID, with a 
false positive of 20% (specificity 80%). The study carried out by Luo et al., 
(2007), compared the diagnostic efficacy of CHr to other markers of ID in 
Chinese premenopausal women. They recommended further studies to 
determine whether CHr should be the preferred screening tool in the early 
detection of ID in larger and unselected population of pre-menopausal 
women and children. 
Most of the studies carried out to examine the clinical utility of RET-He 
mainly focussed on the treatment and monitoring of patients with renal 
disease undergoing dialysis. Most of the findings have indicated that studies 
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would be required in a large population to determine how much information 
could be gleaned. This study would however, consider other disease 
conditions and, more importantly the hospitalised patients to be able to 
identify functional iron deficiency (FID) in disease process especially in cancer 
and inflammation.  
RET-He is a new parameter which provides direct evaluation of the bone 
marrow activity. It mirrors the balance between the demand and supply of 
iron for erythropoiesis. RET-He is easily measurable and has gained merit in 
the diagnosis of FID especially in patients with end-stage renal failure and in 
cancer – related anaemia (Franck et al., 2004). The mean cellular 
haemoglobin content of the reticulocyte (CHr) parameter provided by the 
ADVIA 120 and 2120 directly reflects the recent haemoglobin synthesis in 
bone marrow precursors. However, CHr remains far reaching for many 
laboratories, which is a major disadvantage. Also, the exact threshold values 
have not been established. The cut-off values used for CHr vary from 26 – 32 
pg, depending on the laboratory and the analyser used.  This would invariably 
lead to lack of standardisation. It has been agreed that 29 pg should be the 
exact cut-off value for RET-He, to define deficient erythropoiesis (Miwa, 
2010).   
Although studies examining the diagnostic usefulness of various 
haematological and biochemical parameters have been undertaken, no single 
study of iron status with inflammation have so far included all the 
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measurements of MCV, SF, MCH, RDW, ZPP, Fe, sTfR, RBC-He and RET-He 
indices. Therefore, this study will incorporate all the haematological and 
biochemical parameters and include RET-He and RBC-He. 
 
1.12.8  Peripheral blood smear 
Microscopic examination of peripheral stained blood is used to supplement 
the information obtained from the haematology analyser or cell counters in 
the assessment of iron status. The accurate identification of stained red 
blood cells and white blood cells is done by experienced scientists. IDA is 
recognised from a combination of abnormal iron supply studies and 
microcytic hypochromic red blood cell morphology (Hillman, 1998). Anaemia 
can be classified into three groups depending on the morphology of the red 
blood cells. 
 Microcytic hypochromic features in the smear indicates a decreased 
MCH and MCH concentration of the red blood cell. The morphology in 
the smear would show an expanded central zone of pallor. The small 
hypochromic red blood cells known as microcytes are typical findings 
in IDA, ACD or alpha and beta thalassaemia (Figure 1.3) (Hillman, 
1998). 
 Normocytic normochromic, in acute haemorrhage, 
haemoglobinopathies and HIV related anaemia and ACD. 
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Figure 1.3: Blood smear – normal, microcytic and hypochromic. 
 
 Macrocytic features in the smear are indicated by large oval red blood 
cells usually > 8.5 mm with an increased MCV usually around 120 fL, 
with normal MCH. Likewise, round oval macrocytic cells are slightly 
larger than normal, and the MCV is usually > 95 fL. The presence of 
these cells is indicative of impaired bone marrow DNA synthesis from 
chemotherapy or other inherited disease. Possible causes include liver 
disease, megaloblastic anaemia, B12 or folate deficiency, haemolytic 
anaemia, consequence of reticulocytosis and aplastic anaemia (Figure 
1.4).  
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Figure 1.4: Blood smears – normal, macrocytic and normochromic. 
  
The automated analysis of the blood cells is mostly accurate, reproducible 
and readily available. The value of the use of blood smears in detecting the 
deviation of cells from normal size has decreased, even with the experienced 
haematologists (Dallman, 1984). Jen et al., (1983) concluded that the 
examination of blood smears provides no additional information to the 
indices of patients with microcytic anaemia. Apart from the fact that an 
experienced microscopist is required to report on the cells, the disadvantages 
of non-uniformity of cells, possible over-staining and under-staining present 
issues for consideration. 
 
1.12.9  Mean cell volume and mean cell haemoglobin 
Mean cell volume (MCV) indicates whether a RBC is smaller than normal 
(microcytic), or larger than normal (macrocytic). IDA manifests itself as a 
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microcytic, hypochromic anaemia. Microcytic anaemia, generally defined as a 
MCV < 80 fL, also shows a reduced mean cell haemoglobin (MCH). This may 
be observed either prior to or alongside the haemoglobin reduction (Bolton-
Maggs & Thomas, 2003). MCV represents the average volume of a single 
erythrocyte; its reduction can indicate developing ID in overt anaemia.  MCV 
measurements can be done accurately by the use of an automated 
haematology analyser with impedance or optical light scatter. The British 
Society of Gastroenterology recently revised the guidelines for the diagnosis 
and management of IDA in the general population, and MCV was listed as 
one of the reliable parameters in the diagnosis of IDA in the presence of 
chronic inflammation (Jolobe, 2000).  
It has been suggested by various workers that low MCH correlates better 
with low ferritin levels. Low MCH is therefore considered better than low 
MCV in identifying patients with IDA, because it is less influenced by the cell 
counter and by prolonged storage conditions (Jolobe, 2000). Despite this 
understanding, MCH is still not widely used in routine clinical practice 
(Jolobe, 2000; O’Broin et al., 1990). Although ID is typically characterized by a 
MCV and MCH of < 80 fL and < 26 pg, respectively (Bainton & Finch, 1964), it 
is still a matter of controversy to determine which of the two parameters has 
greater predictive value due to the associated changes in chronic diseases 
and inflammation (Cook, 2003). Decreased MCH hypochromia and increased 
percentage of hypochromic red cells, and reduced MCV increases the 
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sensitivity and specificity when microcytosis, hypochromasia and pencil cells 
are demonstrated (Jolobe, 2000).  
 
To calculate the MCV, expressed in femtoliters, the following equation is 
used: 
MCV =         ________HCT (%) x 10__________   (Eqn 3)        
                   RBC counts (millions/mm3 blood) 
 
To calculate the MCHC, expressed in g/dL, the following equation is used: 
MCHC =                 __HB (g/dL) x 100__                               (Eqn 4) 
                            HCT (%) 
 
 
1.12.10  Acute-phase proteins 
The acute phase response is the innate, physiological and biochemical 
response to the stress of injury, surgery, trauma, inflammation, neoplastic 
growth, immunological disorders or infection. It is denoted by higher plasma 
or serum acute-phase proteins (APPs) (Gitlin & Colten, 1987; Maes et al., 
1997). The role of the acute phase response is to prevent further damage to 
the tissues affected by proteases produced by the pathogens and to initiate 
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the repair process, which is done by modulating T-lymphocyte function and 
the complement system, and also initiation of the inflammatory process 
(Gitlin & Colten, 1987; Mackiewicz et al., 1991). The process of production of 
the APPs is promoted by several intercellular signalling systems, of which the 
most important is the inflammation-associated cytokines, like IL-6, which can 
stimulate APPs in response to varied stimuli. Some of the APPs include C-
reactive protein, α1-antitrypsin, haptoglobin, α1-acid glycoprotein and 
fibrinogen.  
The understanding of the role of APPs in iron status is particularly important 
to allow clinicians to identify any underlying conditions which may prevent 
the treatment of the ID. For example, the role of hepcidin, an iron-regulated 
acute-phase protein, has been implicated in iron homeostasis and anaemia of 
chronic disease, because its increased production in iron overload and 
inflammation is modulated by IL6 and inhibited by TNF- α (Nemeth et al. 
2004). Therefore, in ID, low serum iron and elevated SF in the face of an 
acute phase response indicates some underlying inflammatory condition. 
Bayne et al., (1996) studied the serial changes of serum iron, TIBC, SF and 
CRP, and some other acute phase proteins in various illnesses. They found 
elevated SF appeared in line with high CRP measured in rheumatoid arthritis, 
tuberculosis and sepsis, which suggested that ferritin acted as an acute-phase 
protein, especially in those cases with underlying iron status. The presence of 
acute phase protein has been widely reported in many types of cancers, and 
 53 
 
this obviously interferes in iron metabolism in this group of patients (Denz et 
al., 1992). In the study carried out by Feelders et al. (1998), samples were 
taken from inoperable patients with sarcoma or melanoma for the 
measurements of acute phase protein, elevation in CRP and SF were found to 
parallel each other. CRP level reportedly peaked 4 h after the initiation of an 
inflammatory process. 
The joint WHO/CDC committee recognised the need to consider data on the 
relationship between SF, sTfR and different acute phase proteins to assess 
and determine which best correlated with SF in the face of inflammation. The 
recommendation was that measurement of one or more acute phase 
proteins e.g. C-reactive protein (CRP) and α1-acid glycoprotein could be used, 
being the most frequently used index of inflammation and one that could 
predict changes in the ferritin concentration due to inflammation as inferred 
by many previous workers (WHO/CDC, 2004; Gabay & Kushner, 1999).  
 
1.12.11  C-reactive protein 
C-reactive protein was discovered in 1930 when researchers described a third 
serologic fraction, or “fraction C” that could be isolated from patients 
infected with Pneumococcus that was different from the formerly identifiable 
polysaccharide and nucleoprotein fractions detectable by specific antibody 
response using immunological techniques (Tillet & Francis, 1930). Another 
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decade later, CRP was described as an “acute phase reactant” and was 
elevated in patients with inflammatory stimuli, like myocarditis and 
inflammation associated with rheumatoid arthritis (Abernathy & Avery, 1941; 
Macleod & Avery, 1941). Many previous workers have identified CRP as being 
produced in hepatocytes, and also indicated that an increase in CRP is linked 
to myocardial infarction and ischaemia (Pepys et al., 1978; Baltz et al., 1982). 
CRP is present in the serum of healthy individuals with a value less than 1 
mg/dL. Values above this may indicate some sort of systemic inflammation. 
Up regulation of this protein has also been linked to a rise in interleukin 6 
(IL6) and, to a lesser extent, by tumour necrosis factor TNFα (Darlington et 
al., 1986). As CRP plays an important role in the innate immune cascade, it is 
important to evaluate its role as a marker for detecting the level of 
inflammation in ACD.  
 
1.12.12  Serum hepcidin 
The antimicrobial protein known as hepcidin has been identified and 
implicated to be a key regulator of iron absorption and mobilisation. Hepcidin 
is produced in the liver and secreted into plasma and cleared by the kidneys. 
It causes a decrease in iron release from its stores by down regulating the 
expression of ferroportin (Park et al., 2001; Pidgeon et al., 2001, Ganz, 2006). 
Its synthesis is a result of iron overload and inflammatory stimuli such as 
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interleukin-6 (IL-6) and lipopolysaccharides (Kemma et al., 2005). Decreased 
hepcidin is seen in iron deficiency, accelerated erythropoiesis and hypoxia 
(Nicolas et al., 2002). Although advances in the understanding of the 
pathophysiology of anaemia of chronic disease, including the disturbances of 
iron homeostasis, impaired proliferation and even response to iron therapy 
have been made, to date the bulk of the information has been drawn from 
animal experiments, and the few human studies available were based on in-
vitro experiments using human sera. Therefore, detailed association between 
erythropoiesis and hepcidin has not been fully elucidated in clinical settings 
(Kanda et al., 2008). The study carried out by Dallalio et al., (2003), to assess 
the correlation of hepcidin to anaemia and to clinical iron metabolism 
showed that hepcidin does not correlate as well with ACD. They concluded 
that a better understanding of this protein is required to give some reliable 
information in the diagnosis of ACD.  
 
1.13  Study hypothesis  
Although many studies have been performed to examine the diagnostic 
usefulness of various haematological and biochemical parameters as 
described above, no single study has so far incorporated the measurements 
of MCV, SF, MCH, RDW, ZPP, sTfR, Fe, RET-He and RBC-He indices together. 
Therefore, clinical interest should be focused on the early diagnosis of ID and 
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IDA to prevent and manage systemic breakdown and complications. The 
focus of this study is to evaluate the potential benefits of integrating the 
cytometric indices (RET-He and RBC-He) into the analytical repertoire for the 
evaluation of iron status. 
The aim of this study is to evaluate the cytometric indices RET-He and RBC-He 
in conjunction with the other haematological parameters in the assessment 
of iron status in hospitalised patients.  
 
1.14  Research aims and objectives 
The overall aim of the research was to investigate the diagnostic potential of 
new cytometric indices (RET-He and RBC-He) in conjunction with other 
haematological indices, in assessing disturbances to iron metabolism.  
 To evaluate the stability and reproducibility of the RET-He and RBC-
He, and to assess their ability to measure accurately low iron status in 
patients.  
 To investigate the diagnostic potential of the currently used 
haematological and biochemical screening procedures for detecting 
patients with ID, and to compare these to the erythrocyte and 
reticulocyte haemoglobin content indices. 
 57 
 
 To determine whether the haemoglobinisation indices may be used 
diagnostically to preclude the need for other biochemical assessments 
of iron status. (Note: the study will also address the comparative 
diagnostic value of these indices in the investigation of inflammatory 
conditions which are prevalent in hospitalized patients and selected 
haemochromatosis patients).   
 To evaluate the potential values of erythrocyte and reticulocyte 
haemoglobin content indices and compare with other haematological 
parameters in assessing how patients with haemochromatosis 
respond to treatment. 
 To suggest guidelines for the diagnosis of ID by considering the 
predictive ability of the initial iron screening tests and the added value 
of more specialised and costly tests. 
 To analyse the results and discuss findings. 
 To draw conclusions and make recommendations for change of 
practice and make suggestions for further studies if required. 
 
 
 
 
 58 
 
CHAPTER 2   Materials and methods 
2.0  Overview and study design 
The main aim of this thesis was to investigate the diagnostic potential of the 
new cytometric indices, the reticulocyte (RET-He) and erythrocytes 
haemoglobin (RBC-He) contents in conjunction with other haematological 
indices, in assessing disturbances to iron metabolism.  
The study is a broad assessment of the usefulness of RET-He and RBC-He in 
determining how much information could be gleaned to improve further the 
assessment of iron status in hospitalised patients.  
The research was therefore conducted following different stages of 
investigation and evaluation. In order to overcome the majority of possible 
issues that are likely to be associated with a study such as this, the evaluation 
of different pre-analytical and standard variables were considered at the 
beginning of the study. 
 
2.1  Investigative method 
The method of investigation employed in this research followed the 
established protocols in the haematology and biochemistry sections of the 
clinical pathology laboratory at St James’s Hospital, Dublin, Ireland. 
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Considering the advantages and disadvantages of the methods currently in 
use, the author adapted other analytical methodologies which could 
ultimately lead to a better turnaround time and an improved protocol in the 
assessment of iron status.  
 
2.1.1  Sample collection 
A total of eight hundred samples were obtained for this study, of which 
eighty-nine were from non-anaemic adults to serve as controls to establish 
threshold levels in the parameters tested. Six-hundred and eleven samples 
were from hospitalised patients and one-hundred samples were from 
previously diagnosed haemochromatosis patients currently undergoing 
treatment.  
All samples were drawn by the phlebotomists from the cubital vein using the 
standard vacutainer blood collection system. Subjects were requested to sit 
upright on the chair and their arm was supported to prevent movement. A 
tourniquet was applied 5-8 cm above the venepuncture site. The site was 
swabbed with a 70% alcohol disposable wipe, which was left to air dry for 
about 20 s prior to venepuncture. 
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One K3EDTA blood and two clotted samples were taken from all participants. 
Blood samples drawn into tripotassium EDTA tube and Plain Sarstedt bottles 
were adequately labelled and were used for the analysis.  
 
2.1.2  Control group  
Eighty-nine (11.1%) samples were collected from non-anaemic adults. The 
absence of any systemic inflammation was confirmed in the normal group by 
the value of C-reactive protein (CRP).  
 
2.1.3  Patient group (hospitalised) 
Six-hundred and eleven (76.4%) samples were obtained from hospitalised 
patients at St James’s Hospital Dublin. Cases included in this group were 
symptomatic and asymptomatic conditions, such as gastroenterological 
disease, renal disease, cancer, rheumatoid arthritis and other abnormalities. 
Children and pregnant women were not included in this study. Sample 
selections were sequentially done from the residual blood samples based on 
the clinical diagnosis and information provided by the haematology 
consultants. The author ensured that individual diagnosis provided on the 
request form fulfilled the criteria for sample selection for the study.  
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2.1.4  Haemochromatosis group  
One hundred (12.5%) samples were received from haemochromatosis 
patients currently undergoing treatment. These patients were previously 
diagnosed with the haemochromatosis genetic disorders (HFE). The patients 
also participated in the study as part of the National Surveillance control for 
haemochromatosis patients. Only one tripotassium EDTA blood sample was 
taken for the measurement of the full blood count. The purpose was to 
determine whether RET-He and RBC-He indices could be used to monitor 
treatment and management of the haemochromatosis patient group. A 
decision was taken not to measure serum ferritin on the samples, because 
patients have had serial ferritin and iron measurements over the period of 
diagnosis and treatment, and results were observed to be very high, 
therefore, no new information could have been provided. 
 
2.1.5  Ethical approval 
The study was conducted after approval was obtained following an 
application to the research ethics committee of both St James’s Hospital and 
the Adelaide and Meath Hospital (Appendix A). Patients recruited in this 
study were not personally consulted as the blood samples used were 
requested by the clinicians for clinical investigation rather than specifically for 
research purposes. The added investigations included RET-He, RBC-He, ZPP, 
 62 
 
CRP and sTfR. For this reason, patient consent was not required as indicated 
in the ethics approval documentation. 
 
2.1.6  Power calculation and sample size 
The sample size selected for the study was based on a power calculation 
related to the degree of statistical changes in iron status parameters in the 
early pilot study undertaken, evaluating the RET-He and sTfR in the 
differential diagnosis of anaemia of chronic disease from iron deficiency 
anaemia (Appendix I). The author utilised the outcome of the findings with 
regards to the differential diagnosis between ACD and IDA, and used it to 
detect how many samples were needed.  Statistical power (also called a 
power analysis and typically set at 0.80) is the probability of finding statistical 
differences in the data set.  
The number of samples required with 80% chances to identify ID and IDA 
using RET-He and RBC-He in hospitalised patients with chronic disease, 
inflammation and rheumatoid arthritis, and assuming a two-tailed test at 5% 
significance level. The following results were obtained: 
1). Female: Pilot study results suggested a mean change of 6, with standard 
deviation 28. With a 5% significance level and 80% power, 344 subjects were 
required to show a significant outcome. 
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2). Male: Pilot study results suggested a mean change of 6, with standard 
deviation 23 for male population. With a 5% significance level and 80% 
power, 258 subjects were required to show a significant outcome.  
The power calculation suggests that a total of 602 samples (male and female) 
would be required in order to achieve significant outcome. A total of 611 
samples were obtained from hospital patients with cancer, rheumatoid 
arthritis, gastroenteritis and others with inflammatory response. The increase 
from 602 to 611 was necessary to prevent any inadequate or unsuitable 
samples that may have resulted in not recruiting enough.   611 samples were 
required to show a significant relationship between male and female in the 
hospitalised patients. The margin of error was also considered in the sample 
size calculation. 
 
2.1.7  Identification and classification into disease categories 
Clinical details provided on the database of the Telepath laboratory 
information systems (LIS) were used for identifying the patients. Patients’ 
records were matched accordingly to the information which was available 
under the password protected LIS.  
Patients were anonymised in agreement with the statement submitted to the 
ethics committee. Patient age and the laboratory investigations performed 
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were the only data available within this research. To establish the correct 
diagnosis, presenting signs and symptoms were considered to allow for the 
true classification of disease diagnosis.  
 
2.2  Methodology and principles of analysis 
2.2.1 Full blood counts using flow cytometry methods on the 
Sysmex XE-2100TM 
 
The Sysmex XE-2100TM is the haematology analyser used in this study for the 
full blood count (FBC) analysis. The analyser uses fluorescence flow 
cytometry and hydrodynamic focusing technology to measure the standard 
five part differential, immature granulocytes (metamyelocytes, myelocytes 
and promyelocytes), nucleated red blood cells (NRBC), reticulocyte count, 
immature reticulocyte fraction and “optical” fluorescent platelet count. The 
combination of side scatter (inner cell), forward scatter (volume) and 
fluorescence intensity of nucleated cells has brought an improvement to how 
normal and abnormal cells are classified, thereby removing the need for 
manual counting. The performance evaluation of this analyser, as evaluated 
by some workers, found there was excellent correlation in linearity, and the 
reproducibility produced good results with insignificant carryover, when 
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compared with results obtained from Sysmex SE 9500TM  and the manual 
counting (Briggs, et al., 2001; Brugnara et al., 2006).  
RET-He and RBC-He are available as an optional feature on the analyser, it 
measures the incorporation of iron into the red cell to assist in anaemia 
evaluation and management. FBC were performed according to the 
established standard operating procedures in the haematology laboratory, 
and in accordance with the Sysmex-XE2100 (Kobe, Japan) manufacturer’s 
instruction. The methods were optimised to allow further cytometric analysis 
of the reticulocyte and erythrocyte haemoglobin measurements. 
The Sysmex XE-2100TM analyser used throughout this study was the same 
analyser routinely used in the haematology laboratory of St James’s Hospital, 
Dublin. The analyser was calibrated and controlled at the beginning of the 
study. Reagents were loaded and replenished as required on the analyser for 
the purpose of this project. 
Reagents for erythroblast measurement are Stromatolyser-NR, lytic agent 
and staining liquid. The surfactant contained in the Stromatolyser-NR lytic 
agent lyses the erythrocytes, exposes the erythroblast nuclei, and uses the 
leucocyte membranes. This agent is used to distinguish erythroblast from 
leukocytes, especially the lymphocytes. The technology uses proprietary 
polymethine dye, which acts by penetrating the cells and staining the nucleic 
acid of the cytoplasmic organelles.  
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Reagents for white blood cell (WBC) 4-differential counting known as 
Stromatolyser-4DL, Stromatolyser-4DS were loaded on the Sysmex XE2100TM 
analyser accordingly. The surfactant contained in Stromalyser-4DL lyses and 
dissolves erythrocytes and platelets. Following this process, the dye 
contained in the Stromatolyser-4DS enters the WBC, and allow the staining of 
the nucleic acid and cytoplasmic organelles, such as the endoplasmic 
reticulum, to take place. 
The following steps were undertaken using the manual mode to measure full 
blood counts on the Sysmex XE-2100TM with the incorporation of the 
reticulocyte parameters.  
 To analyse an EDTA blood sample, the manual option was used on the 
analyser. Sample barcode numbers were scanned using the hand held 
barcode scanner. EDTA samples were presented to the sample probe 
on the analyser in the order in which they were obtained. The sample 
was removed and the manual rinse cup lowered to wash and dry the 
sample probe.  
 Internal quality controls (IQC) were treated the same every time a 
measurement was performed to ensure reliability and reproducibility. 
 Results obtained were displayed on the Sysmex XE-2100TM LCD 
screen. A sample of the printout is presented in the Appendix E. The 
controls were checked visually to ensure every parameter was within 
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the range originally configured, and ‘OK’ was pressed. This action sent 
the patient’s result to the laboratory information system. 
2.2.2  Stability studies procedure 
Stability studies were undertaken to assess the effect of prolonged storage at 
different temperatures on the following parameters, RBC-Y, RET-Y, MCV, 
MCH and HB. The Sysmex XE-2100TM was used for the measurements of 
K3EDTA blood samples to assess the effect of storage at temperatures of 4
oC, 
20OC and 30oC for a period of 96 h. Fifteen K3EDTA samples were selected for 
this study, (normal and abnormal samples). All samples were tested at 
baseline when received in the laboratory and up to 96 h in order to assess 
changes over time. 
Individual K3EDTA samples were aliquoted into three plain sample tubes 
capped, and labelled according to the information contained on the primary 
samples. Barcode labels were also given to each sample and the 
corresponding form to allow easy tracking and identification. Tubes 
containing equal sample volumes were stored at regulated temperatures of 
4oC (refrigerator), 20oC and 30oC (water bath). The temperatures were 
monitored by the use of thermometers and any sudden changes in the 
refrigerator temperature were monitored centrally using the pathology 
temperature monitoring systems. Serial measurement for RBC-Y, RET-Y, MCV, 
MCH and HB on the stored samples were performed over a period of four 
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days. Measurements were performed at the same time on each day to allow 
for equal storage conditions.  
 
2.2.3  Ferritin assay using chemiluminescent technology 
Serum ferritin was analysed on the Beckmann Coulter Access TM 
immunoassay systems. The principle of the assay is based on 
chemiluminescent technology. The principle is a one step sandwich 
technique, where paramagnetic particles coated with goat anti-mouse 
IgG/anti-ferritin monoclonal antibody (MAB) complexes are combined with 
goat anti-ferritin alkaline phosphatase conjugate (AFCP), which bind to 
ferritin molecules in the sample, and the resulting complex in the formation 
is an insoluble aggregated turbidity, the signal produced is directly 
proportional to the concentration of ferritin in the sample. The method has 
been found to correlate extremely well with the reference enzyme 
immunoassay (EIA) methodology with good precision (CV < 5%), and has an 
excellent sensitivity of 0.2 ng/mL 
All samples, except those from haemochromatosis patients, were labelled 
with unique barcode identification numbers, centrifuged and the serum 
decanted from the primary sample tube into a plain tube which was also 
numbered and marked with the patient’s name and date of birth.  
 69 
 
An important part of any assay analysis is the standardisation of the 
methodology employed. Prior to the analysis, the Beckmann Coulter AccessTM 
analyser was calibrated to ensure that every component and result obtained 
was reliable. Calibration was performed using the six-point calibration 
procedures provided by the manufacturer. The calibrators were S0, S1, S2, S3, S4 
and S5. The assigned values were 0, 10, 50, 200, 500 and 1500 ng/mL 
respectively.  
Three levels (Level 1, 2 and 3) of commercially prepared controls known as 
Liquid Assayed Immunoassay controls from Medical Analysis Systems Inc 
MASTM were measured on the Beckmann Coulter AccessTM analyser on a daily 
basis both in the morning and afternoon.  
Serum samples were analysed on the Beckmann Coulter AccessTM analyser 
platform within 24 h. The analysis was performed using standard ferritin 
assay reagent kits and performed according to the manufacturer’s 
instructions (Appendix G). 
 
2.2.4  ELISA methods for soluble transferrin receptor measurement 
Initially, soluble transferrin receptor (sTfR) measurements were carried out 
based on the enzyme-linked immunosorbent assay (ELISA) method. ELISA is 
described as a method whereby antigen or antibody is bound to a solid 
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surface or a latex particle. The measurement of sTfR was carried out using 
the reagent kit from Quarantine® IVD® in-vitro diagnostic produced by R&D 
systems. The principle of the assay was based on the microplate sandwich 
enzyme-linked immunosorbent assay (ELISA), by using two different 
monoclonal antibodies specific for the quantitative determination of sTfR 
concentrations in human serum and plasma. This assay was slightly different 
from that of Briggs et al., (2001), where they employed a particle-enhanced 
immunoturbidimetric assay, which was based on the immunoreactions 
between sTfR and transferrin specific antibodies (Suominen, et al., 1999).  
The method used in this study was based on the R&D assay and similar to the 
approach adopted by Flowers et al., (1989). All reagents were prepared as 
described in the kit insert (Appendix H). The wash buffer concentrate was 
warmed to room temperature, and mixed gently to ensure dissolution of all 
crystals. To make up the working buffer solution, 20 mL of the wash buffer 
concentrate was added into 480 mL of deionised water to 500 mL. Each of 
the three vials of lyophilised human sTfR in buffered animal serum controls 
were also reconstituted using 200 µL of deionised water and vortexed, 
allowed to stand for thirty minutes and vortexed again before use. 96-well 
polystyrene flat bottomed microplate (12 strips of 8 wells) coated with a 
mouse monoclonal antibody against sTfR were used for all of the ELISA 
measurements. Aliquots, 100 µL, of the assay diluents were dispensed into 
each well of separate micro titre plates using a multi-channel pipette, and 20 
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µL of the calibrators, controls and samples were added to each well. The 
sampling procedure was performed uninterrupted and was completed within 
15 min. The plate frame was then tapped gently to ensure adequate mixing 
of the contents of each well. The assays were covered with an adhesive strip 
and were incubated at room temperature (18–25oC) for 1 h. Following 
incubation, the plates were aspirated and washed four times with wash 
buffer using the auto washer. Once excess liquid had been removed from the 
plate, 100 µL of sTfR conjugate was added to each well; plates were then 
covered and incubated at room temperature (18–25oC) for 1 h. When the 
incubation time was complete, the washing step was repeated, and 100 µL of 
substrate was added to each well and incubated at room temperature (18–
25oC) for 30 min; direct light was avoided at every stages of incubation. The 
final step was the addition of 100 µL of stop solution, and the plates were 
gently tapped to ensure thorough mixing of the contents and the optical 
density of each well was read within 30 min on a Ceres 900i microplate 
reader set at 450 nm, according to the manufacturer’s instructions. A 
standard curve was generated and results were automatically calculated by 
means of the standard curve (Appendix H). All sera were tested in duplicate 
and the arithmetic mean of any optical density calculated before further 
analysis was undertaken. 
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Three controls were provided within the sTfR assay kit and were analysed 
alongside the patient samples in the same manner as the methodology 
described above. Expected values provided were as follows: 
Table 2.1:  sTfR R&D assay: manufacturer control ranges 
Control Expected range 
Level 1 5.20–7.60 nmol/L 
Level 2 12.7–18.5 nmol/L 
Level 3 34.6–48.8 nmol/L 
 
The ELISA method described above is used widely in clinical practice and was 
the method of choice for measuring the sTfR concentration in this study. 
However, there have been many published reports detailing the 
inconsistency and lack of standardisation between the methods of sTfR 
assays, as a result of proteins used in the preparation of standards in 
different methods. Previous workers claimed there has been possible 
overestimation of sTfR in patient samples (Brugnara, 2003; Kogan et al., 
2007).  
2.2.5 Zinc protoporphyrin assay using the haematofluorometry 
principle 
Measurements of ZPP were performed using a ZP Haematofluorometer, 
Model 206D (Aviv Biomedical, Inc). The ZPP Haematofluorometer analyser is 
 73 
 
a bench top single channel front surface photofluorometer. The excitation 
source was a 12 V, 50 W quartz halogen lamp, and the lamp was turned on 
automatically each time the ‘measure’ button was pressed, and the light 
remained throughout the 9 s measurement cycle. The light was filtered by 
means of an interference filter transmitting at 415 nm, and the excitation 
light was directed at the drop of blood on the coverslip to enable minimum 
fluorescence. The light emitted was collected in a vertical direction, which 
passed through a narrow band interference filter transmitting at 596 nm, and 
the result was displayed on the 13 mm 7 segment LED readout. 
Three AVIV ZPTM red blood cell commercially prepared control vials (low, 
medium and high) were used throughout the study. These controls represent 
actual samples drawn from normal, moderately anaemic and severely lead 
intoxicated individuals. The expected results for each control were quoted on 
the packaging inserts in µmole ZP/mole Haem (Table 2.2). 
                                       Table 2:2:   Ranges for internal quality control for ZPP 
Control Number  µmole ZP/mole Haem 
Level 1 83  (+/- 8) 
Level 2 144 (+/- 14) 
Level 3 295 (+/- 29) 
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Evidence from some workers suggested that washing of samples for ZPP 
estimation is a necessary action before the analysis. Studies in the Mannheim 
Clinic at the University of Heidelberg, Germany, found a list of 60 drugs that 
caused falsely elevated ZPP readings in whole blood, and some examples 
include Claforan, Endoxan and Zantic. Therefore, washing the cells of samples 
before the analysis of ZPP will remove any fluorescent interference that may 
result in false ZPP elevation (Hastka et al., 1992). 
The process of ZPP measurement of patient samples involved pipetting 100 
µL of EDTA whole blood into a clean labelled polythene tube (13 x 75 mm). 
Two mL of saline solution was added to the tube using a pipette, and 
aspirated up and down to ensure a homogenous mixture. The sample was 
covered using parafilm and centrifuged at 2000 rpm for five minutes. 
Following this step, the parafilm was removed and the supernatant 
discarded, leaving only a small volume of saline over the red cells. This was 
roughly equivalent to the initial sample volume. A clean Pasteur pipette was 
then used to place approximately 20 µL of sample onto a clean coverslip, 
already seated on the haematofluorometer slide holder, and the ‘MEASURE’ 
button was pressed. The result obtained was recorded for each sample.    
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2.2.6  Serum iron assay using the colorimetric principle 
Serum iron was measured on the Roche automated chemistry analysers 
(Roche Diagnostics GmbH, Mannheim) using a colorimetric principle. The 
principle involves the liberation of Fe3+ ions from the transferrin complex, 
and the reduction of Fe3+ to Fe2+ ions, which was followed by the reaction of 
Fe2+ to give a coloured complex, which was read photometrically. The 
method was based on the FerroZine method without deproteinisation. 
All the reagents and working solutions used were as per the manufacturer’s 
instructions (Appendix D). Reagents (R1) and (R2) were supplied to use. R1 
contained citric acid, 200 mmol/L thiourea: 115 mmol/L and detergent, while 
R2 contains 150 mmol/L sodium ascorbate, 6 mmol/L FerroZine and 
preservative was also added. All reagents were stored at 2-8oC. Once opened 
and loaded on the analyser, the stability was for 28 days. The analyser was 
configured to perform two points calibration using calibrator for automated 
systems (CFAS) (Roche Diagnostics GmbH, Mannheim), precinorm and 
precipath controls as supplied by Roche (Roche Diagnostics GmbH, 
Mannheim). The limits of detection were determined by calculating the value 
lying 3SDs above that of the lowest standard (standard 1 + 3 SD, 
repeatability, n = 21). 
Serum samples collected for this project were analysed for serum iron 
according to the methodology already in use in the biochemistry laboratory. 
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Internal quality control results were checked on the analyser based on the 
Westgard rule to determine the analytical precision before the patient 
samples were run.  
 
2.2.7  C-reactive protein (CRP) using the nephelometric principle 
C-reactive protein (CRP) was measured on all the patient’s samples using a 
nephelometric method. The nephelometric principle uses the laser light 
scattering by immune complexes to measure CRP. Nephelometric and 
turbidimetric assays have been shown to have excellent correlation (Luis et 
al., 2003). The analysis followed the established protocol in the Immunology 
section of the laboratory. The Behring Nephelometer II (Dade Behring Inc., 
Deerfield, IL) is an automated analyser for the determination of plasma 
protein. It measures the agglutination of particles by quantifying scattered 
light and the detection limit is greater than 0.0175 mg/dL. Serum samples 
collected for this project were analysed for CRP according to the 
methodology already in use in the immunology laboratory. IQC results were 
checked to determine the analytical precision before the patient samples 
were tested.  
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2.3  Statistical analysis 
Statistical analysis was performed using SPSS version 18. Data collected 
during the study was recorded in excel spreadsheets and imported to SPSS. 
Statistical comparisons were performed using independent t-tests and 
analysis of variance (ANOVA) where applicable.  
The main aim of data analysis was to investigate the diagnostic potential of 
the currently used haematological and biochemical screening procedures for 
detecting ID. Therefore, data was evaluated using descriptive analysis, 
normal and skewed distributions of continuous variable were expressed as 
mean and median (±) standard deviation (SD) respectively. Receiver 
operating characteristic (ROC) analysis was utilised to illustrate the diagnostic 
performance of RET-He and RBC-He. Diagnostic plots were used within the 
SPSS and the cut-offs point for individual parameters were applied in line 
with the established guidelines. SF < 20 ng/mL was used to classify patients 
as having ID, while haemoglobin < 11.5 g/dL for female, and < 13.5 g/dL for 
male was used to classify patients as having IDA. RET-He and RBC-He of 28 pg 
were also used for the purpose of determining the threshold for upper of 
lower limits, and this was also in agreement with findings by others (Thomas 
& Thomas et al., 2002; Brugnara, 2003).  
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Chapter 3   Results 
 
3.0  Introduction 
This chapter describes the results of the study of the frontline haematological 
and biochemical indices of iron deficiency in comparison with the cytometric 
indices, reticulocyte (RET-He) and erythrocyte haemoglobin (RBC-He) content 
in iron status. 
The main objectives were to demonstrate the use of RET-He and RBC-He as 
key independent indicators of iron status, and to compare these with the 
gold standard diagnostic tests, which is SF in most cases, then decide at what 
stage the gold standard becomes unreliable to the extent of misleading the 
physicians. The potential use of both indices in the monitoring of 
haemochromatosis patients was evaluated. The stability and reproducibility 
of RBC-He and RET-He and MCV will also be reported within this chapter.  
 
3.1  Study Population 
The total sample population used in this study was 800, of which eighty-nine 
(11.1%) samples were obtained from normal individuals. A total of 611 
(76.4%) samples were from male and female patients with the following 
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diagnoses:  rheumatoid arthritis, gastroenteritis and renal conditions at the St 
James’s Hospital. One-hundred samples (12.5%) were also received from 
haemochromatosis patients, who were part of the pilot studies in the Irish 
National Blood Centre and St James’s Hospital, Dublin to determine if the 
RET-He and RBC-He could contribute to treatment and diagnosis, relative to 
other markers of iron indices. All samples were received over a period of five 
months.  
Baseline characteristics for the groups of patients used are described below 
showing the parameters, mean and standard deviation. The normal 
individuals all had normal red cell indices and are grouped according to 
gender. The biochemical parameters were found to be normally distributed 
within the control group. This was used to determine the gender specific 
intervals for this study.    
 
 
 
 
     
Figure 3:1. Flow chart showing study population 
Total no of samples (n = 800) 
PATIENTS (N=611) 
Female 340 
(55.6%)  
Male     271 
(44.4%) 
Hospitalised 
patients 
 
 
 
 
 
CONTROLS (N = 89)  
Female 58 (65.2%) 
Male 31     (34.8%) 
No ID/IDA. No 
inflammation 
 
HAEMOCHROMATOSIS 
(N=100) 
Female 51 (51%) 
Male 49     (49%) 
Patients undergoing 
treatment 
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3.2  Stability and reproducibility assessment 
Analysis within this study depended on the reproducibility of the measured 
parameters RET-He and RBC-He. Therefore, the first set of analyses 
performed was to examine the changes in RET-He and RBC-He (Table 3.1). 
   
 Table 3.1: Reproducibility results for the reticulocyte and erythrocyte indices 
 RET-He (pg) RET-He (pg) RBC-He (pg) RBC-He (pg) 
SD    CV % SD  CV (%) 
Within-run precision 0.41 1.33 0.12 0.9 
SD of the run means 0.38 1.25 0.30 1.0 
SD of daily means 0.23 2.94 0.19 0.8 
Total Imprecision 0.82 2.85 0.30 1.24 
 
The precision data were collected over 10 days and showed RET-He total 
imprecision to be SD = 0.82 pg (CV 2.85%). The total imprecision for RBC-He 
showed an SD = 0.30 pg and CV 1.24% as shown in the table above. Results 
shows that precision is in agreement with the manufacturer specifications for 
the parameters measured. All the parameters showed excellent precision, 
with the coefficient of variation of 2.85% and 1.24% for RET-He and RBC-He 
respectively. Imprecision obtained for both parameters is therefore 
negligible. A CV < 5% is an acceptable imprecision for these parameters. Each 
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run contained internal quality control samples, used as part of the laboratory 
protocol, and all results were within specified limits of acceptance.  
The blood specimens used for the evaluation were residual materials from 
patient samples sent to the laboratory for routine testing. All samples were 
drawn into vacutainer K3EDTA tubes and maintained at room temperature, 
except during stability studies, in which case samples were stored at 
controlled temperature as previously described. 
 
3.3  Stability 
A total of fifteen samples (normal and anaemic) were selected for the 
purpose of evaluating the stability of the HB, MCV, MCH, RET-He and RBC-He. 
Samples (S2, S3, S4, S6, S7, S8 and S15) were considered normal, while 
samples (S1, S5, S9, S10, S11, S12, S13 and S14) were considered anaemic 
based on the HB measurements. FBC values were initially measured when 
samples were received in the laboratory. Aliquots of the selected samples 
were then stored at 4oC, 200C or 300C. All samples were tested at baseline 0, 
24, 72 and 96 h to determine if each parameter would change over time. 
Each run contained internal quality control samples used as part of the 
laboratory protocol. In the context of sample stability, statistical analysis 
cannot differentiate between changes due to sample degradation and the 
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analytical variance due to the limitations of the specified parameters (Imeri 
et al., 2008).  
The figures shown below (Figures 3.2i-3.2v) were obtained from the stability 
studies performed using the measurement of HB, MCV, MCH, RET-Y and RBC-
Y on fifteen samples (S1–S15) obtained from normal and anaemic subjects in 
different categories. The raw data obtained for the stability studies are 
presented in Appendix F.   
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 Figure 3.2i: Indicates stability of haemoglobin (g/dL) over 4 days.   
HB (g/dL) was considered stable over time at 40C, 200C or 30 0C. Changes 
observed were negligible as shown in Figure 3.2i. Analysis of variance 
(ANOVA) indicates no significant difference between samples S1 – S15 and 
between temperatures (P < 0.05). The changes observed was not clinically 
significant and, would not be expected to have serious effect in the 
identification of patients as either having IDA or not. Delay in sample receipt 
around this period is not expected to affect the result adversely. 
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Figure 3.2ii: Indicates stability of mean cell haemoglobin (pg) over 4 days. 
MCH was considered relatively stable over time for samples S1 – S15 at 40C, 
200C or 30 0C. Changes observed were negligible as shown in Figure 3.2ii 
above. ANOVA indicates no significant changes in MCH (pg) parameter over 
time with P < 0.05. Subsequent analysis indicates results for room 
temperature (RT) to be slightly lower than results obtained at 40C, 200C or 30 
0C. The changes observed were not deemed to be clinically significant and 
would not be expected to affect patient’s classification. 
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      Figure 3.2iii: Indicates stability of mean cell volume (fL) over 4 days 
The MCV (fL) was unstable after 24 h, this was due to significant changes in 
cell size over time at 40C, 200C or 30 0C. There were significant changes 
observed in the MCV (fL) stability for S1 – S15 as shown in Figure 3.2iii. 
ANOVA indicates significant changes in MCV parameter over time with P = 
0.06. Repeated analysis indicates the initial results obtained for normal 
samples (S2, S3, S4, S6, S7, S8 and S15) became higher after 24 h. Also, MCV 
values in anaemic samples (S1, S5, S9, S10, S11, S12, S13 and S14) became 
normal after 24 h. The changes observed were considered clinically 
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significant and, could potentially affect the classification of patients and 
clinical decision regarding the iron status of an individual. 
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                                Figure 3.2iv: Indicates stability erythrocyte haemoglobin content (pg) over 4 days. 
RBC-Y is considered stable over time for sample S1 – S15 at 40C, 200C or 30 
0C. There were negligible changes observed in RBC-Y (pg) values as shown in 
Figure 3.2iv. ANOVA demonstrate there were no significant changes with P < 
0.05. Repeated analyses indicates marginal difference between results 
obtained at room temperature with those obtained at 40C, 200C or 30 0C. The 
difference would not have any clinical significant on patient’s results. 
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Figure 3.2v:  Indicates stability of reticulocyte haemoglobin content (pg) over 4 days. 
RET-Y is considered stable over time for samples S1 – S15 at 40C, 200C or 30 
0C. There were negligible changes observed as shown in Figure 3.2v. Analysis 
of variance (ANOVA) was used to demonstrate that there was no significant 
change in RET-Y parameter over time with P < 0.05. Repeated analysis 
indicates results at RT compares with those obtained at 40C, 200C or 30 0C. 
The change observed is not clinically significant. 
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3.4 Haematological and biochemistry indices in the 
control group 
 
The normal subjects within this thesis consist of 89 normal adult subjects (58 
female, 31 male) without inflammation (CRP < 5 mg/L). The purpose of using 
these samples was to express the differential results obtained from male and 
female populations. This also confirmed the understanding gained from many 
studies, that ID is most common amongst women, especially female of ages 
15–49 years old. It is difficult to establish a reference algorithm for the 
diagnosis of ID for both male and female, even in healthy population as seen 
in the tables below. The results of male and female should therefore be 
considered separately (Siti-Noor, et al., 2006; Tolentino & Friedman, 2007). 
Although the numbers considered here may not be sufficient to establish the 
cut-offs for SF, it does agree with the 5th and 95th percentile values for SF 
quoted for female (13-130 ng/mL) and male (30–400 ng/mL) (Lotz et al., 
1997). The ranges quoted by Beckmann Access (male: 24 – 336 ng/mL; 
female: 11 – 307 ng/mL) are also similar. 
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3.5 Haematological and biochemical indices in the 
patients group 
The aim of this study was to determine the diagnostic performance of RET-He 
and RBC-He in comparison with the traditional biochemical and 
haematological indices of iron deficiency, that is, SF, HB, MCV, MCH, ZPP, and 
sTfR. Therefore, 611 samples were obtained from patients aged between 18–
90 years (271 male; 340 female). Patients were admitted to the following 
departments at the St James’s Hospital, Dublin: Oncology, Urology and 
Internal Medicine.  
Male and female patients were treated separately. They were classified as 
either having ID or IDA using SF concentration and haemoglobin levels 
respectively. 
The diagnostic criteria for anaemia in IDA vary between studies. The WHO 
definition for anaemia is based on age, gender and even pregnancy status. 
Therefore, some of the criteria set out may not be applicable across every 
study performed. The HB level < 13.5 g/dL (men) and < 11.5 g/dL (female) 
were used to define IDA in this study. It is also important to note that 
pregnant women were excluded from participation in the study. SF ≤ 20 
ng/mL was used to classify patients with ID. 
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Table 3.2: Haematological and biochemical characteristics for 58 normal subjects   
and 340 female patients. 
Parameters Normal subjects  
Ranges (Mean) 
Iron deficient 
subjects  
Ranges (Mean) 
 
Reference  
Ranges used 
Haemoglobin  (g/dL) 11.5 – 15.9 (13.7) 6.8 -16.5      (11.3) 11.5 – 16.0 
Mean cell volume (fl) 80.1 – 93.4 (88.3) 66.0 - 106.0 (84.1) 78.0 – 101.0 
MCH (pg) 25.0 – 35.0 (30.2) 15.0 - 38.2   (28.5) 27.0 – 33.0 
MCHC (g/dL) 27.6 – 35.7 (32.1) 21.5 - 35.6   (30.7) 31.0 – 35.0 
RDW (%) 11.9 – 18.9 (16.5) 12.0 - 32.0   (16.1) 11.5 – 14.5 
RET-He  (pg) 27.5 – 34.6 (31.4) 15.2 - 39.8   (24.6) 23.0 – 32.0 
RBC-He (pg) 28.3 – 32.5 (30.5) 14.3 - 39.0   (24.8) 23.0 – 32.0 
ZPP (µmole zp/mole 
haem) 
58.0 – 91.0 (64.3) 22.0 - 509.0 (90.3) 60.0 – 80.0 
Ferritin (ng/mL) 19.4 – 347.1 (65.8) 2.1 - 674.0   (52.0) 12-0 – 200.0 
Iron (µmol/L) 4.0 – 58.4 (32.1) 1.2 - 81.0     (13.0) 9.5 – 29.9 
sTfR (mg/L) 8.2 – 27.3 (18.4) 2.3 - 102.2   (26.5) 8.7 – 28.0 
sTfR Index 7.42 – 22.4 (15.3) 1.7 - 291.1   (25.1) 12.0 – 14.5 
 
Table 3.2 above presents the overall descriptive data obtained for the 
haematological and biochemical parameters measured in the 340 female 
samples in this study. Using the criteria described in section 3.5 above, 
patients were classified into either ID or IDA. 
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Keywords: Haemoglobin (HB); erythrocyte haemoglobin content (RBCHE); reticulocyte 
haemoglobin content (RETHE); mean cell volume (MCV); mean cell haemoglobin (MCH); iron; 
and iron deficiency status (ID). 
       Figure 3.3: Box plot for female population with ID. 
 
Figure 3.3 above shows the box and whisker plots indicating the preliminary 
data spread of iron indices distribution versus ID status in the female patient 
population and also indicates the potential values of individual parameters. 
The bottom and the top of each box represent lower and upper quartiles 
(25th and 75th percentiles respectively). The horizontal line inside the box is 
the median value (50th percentile) for the data distribution for each 
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parameter presented in the plot. The whiskers at both ends of the box 
represent the minimum and maximum (5th and 95th percentile) of all data. 
Data not included are shown as stars and are known as outliers. The data 
distribution for both RET-HE and RBC-HE seem fairly symmetric as the ‘Box’ 
sits in the middle of the range of values for both ID (Present) and ID (Not 
Present), and the whiskers are approximately equal in length. HB is negatively 
skewed, and the median is grouped to the left in the negative direction. MCH 
is also positively skewed. Based on the spread in the Figure 3.3 above, the 
preliminary display indicates that ID identification using MCV, HB, LOGFERR 
and MCH may not be as good as the spread for RET-He and RBC-He.  
 
 
 94 
 
 
Keywords: Haemoglobin (HB); erythrocyte haemoglobin content (RBCHE); reticulocyte 
haemoglobin content (RETHE); log ferritin (LOGFERR); mean cell volume (MCV); mean cell 
haemoglobin (MCH); iron deficiency anaemia status (IDASTATUS). 
         Figure 3.4: Box plot showing for female population with IDA. 
 
The box and whisker plots as shown in Figure 3.4 above indicates the spread 
of the preliminary data for the iron parameter in female patient population 
with IDA. The bottom and the top of each box represent lower and upper 
quartiles (25th and 75th percentiles respectively). The horizontal line inside 
the box is the median value (50th percentile) for the data distribution for each 
parameter presented in the plot. The whiskers at both ends of the box 
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represent the minimum and maximum (5th and 95th) of all data. Data not 
included are shown as stars and are known as outliers. The data distribution 
for both RET-He and RBC-He are fairly symmetrical, as the ‘Box’ sits in the 
middle of the range of values for both IDA (Yes) and IDA (No), and the 
whiskers are approximately equal in length. HB is negatively skewed, and the 
median is grouped to the left in the negative direction. MCH is also positively 
skewed. Based on the spread in Figure 3.4, there was no distinct 
identification of IDA using LOGFERR and MCH. The aggregate in the box plots 
indicates that RET-He and RBC-He could potentially identify IDA, HB and MCV 
appear promising.  
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A receiver-operator characteristics (ROC) curve was constructed with 
reference to the criteria for classifying patients into either ID or IDA for the 
340 female patients. 
 
         Figure 3.5: ROC for female population with ID classification using SF 
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                 Table 3.3:  AUCROC, sensitivity and specificity for iron indicators in female ID 
 
 
 
 
 
 
Tables 3.3 as shown above presents the sensitivity and specificity of each 
parameter. SF ≤ 20 ng/mL was chosen to classify patient as having ID. The 
diagnostic performances of RET-He and RBC-He in ID were compared with 
the traditional parameters of ID. By using RET-He ≤ 28 pg, ID in female 
patients within this study could be diagnosed with a sensitivity of 89.6% and 
a specificity of 58.0%. Also, using a cut-off level RBC-He ≤ 28 pg, ID could be 
diagnosed with the sensitivity of 88.6% and a specificity of 57.0%. The AUC 
for SF is 0.99, and SF has 100% sensitivity and specificity. HB has a sensitivity 
of 67.8% and a specificity of 59.0% ability to identify female patients with ID. 
In inflammatory condition, the sensitivity and specificity of SF may become 
unreliable, this is where the real advantage of RET-He and RBC-He would be 
seen.  
Parameters  Cut-Off 
Point 
AUCROC Sensitivity 
% 
Specificity 
% 
 HB (g/dL) ≤ 11.5 0.66 67.8 59.0 
MCV (fl) ≤ 80 0.64 39.6 83.0 
RET-HE (pg) ≤ 28 0.72 89.6 58.0 
RBC-HE (pg) ≤ 28 0.72 88.6 57.0 
ZPP (µmole zp/mole 
haem) 
≤ 70 0.43 59.4 28.0 
SF (ng/mL) ≤ 20 0.99 100.0 99.9 
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Figure 3.6: ROC for female population with IDA classification using HB 
 
ROC constructed as shown in Figure 3.6 above indicates the performance of 
each parameter for female patients with IDA classification. A cut-off point of 
HB ≤ 11.5 g/dL was chosen as the value most suited and close to the highest 
sensitivity for distinguishing IDA.  
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     Table 3.4:  AUCROC, Sensitivity and specificity for iron indicators in female with IDA 
Parameters Cut-off 
Points 
AUCROC Sensitivity 
% 
Specificity 
% 
HB (g/dL) ≤ 11.5 0.99 100.0 99.9 
MCV (fl) ≤ 80 0.96 61.0 98.0 
RET-HE (pg) ≤ 28 0.87 84.0 72.0 
RBC-HE(pg) ≤ 28 0.86 82.0 71.0 
ZPP (µmole zp/mole 
haem) 
≤ 70 0.37 55.2 24.0 
SF (ng/mL) ≤ 20 0.63 71.4 56.0 
 
Tables 3.4 above present the sensitivity and specificity of each parameter. HB 
< 11.5 g/dL was chosen to classify female patient as having IDA. The 
diagnostic performances of RET-He and RBC-He in IDA were compared with 
the traditional parameters of ID. By using RET-He 28 pg, IDA in female 
patients within this study could be diagnosed with a sensitivity of 84% and a 
specificity of 72.0%. Also, using cut-off level RBC-He 28 pg, IDA in this group 
could be diagnosed with the sensitivity of 82.0% and a specificity of 71.0%. 
The AUC for HB is 0.99, and has a sensitivity of 100% and a specificity of 
99.6% ability to identify female patients with IDA.   
 
 
 
 100 
 
3.6  Thomas diagnostic plots 
The combined results of the iron indices can be displayed in a simple scatter 
plot known as ‘Thomas plot’ as coined by its inventors (Thomas & Thomas, 
2002). There are four quadrant areas on the plots labelled (A, B, C and D) as 
shown in Figure 3.7 below. FID can be differentiated from classic ID in 
hospitalised patients using this diagnostic approach. Quadrant A indicates 
patients with ACD with full iron stores. The patients within this quadrant are 
likely to have anaemia, despite normal haemoglobin production. Quadrant B 
is a transitional area, which shows possible latent iron deficiency. In quadrant 
C, ACD is more likely presented with full iron stores. This means, we can 
diagnose FID caused by ACD where reticulocyte cannot appropriately utilise 
iron for erythropoiesis. Finally, quadrant D would display an uncomplicated 
and classic ID.  
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(A)  
 
Iron repletion, normal 
erythropoiesis 
(B)  
 
Patient may have reduced iron 
supply. But have not begun iron-
deficient erythropoiesis. 
Normal haemoglobinisation of red 
cells. 
 
 
 
 
(C) 
 
Functional ID in iron repleted state. 
Decreased haemoglobinisation of 
red cells 
(D)  
 
Depletion of iron storage. 
Decreased haemoglobinisation of 
red cells 
 
 
 
 
 
 
 
 
Figure 3.7:   Thomas plots showing four quadrants and interpretations. 
 
3.7  Assessment of iron indicators in female patients 
To assess the diagnostic relationship between the biochemical and 
haematological parameters, the following diagnostic plots (Figures 3.8 – 3.19) 
were used to indicate the ability of a combination of parameters to correctly 
classify female patients with IDA and ID, even in the presence of 
inflammation. Parameters were also examined and plotted using the 
appropriate cut-offs to evaluate individual ability in iron status evaluation. 
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                                 Figure 3.8: Plot for RET-HE versus HB in female (IDA) with or without inflammation 
 
Figure 3.8 above compared RET-He with HB results in female patients with 
IDA classification. This was to emphasise the role of RET-He in the 
identification of patients with IDA in the presence of inflammation. Quadrant 
A represent female patients with normal RET-He and low HB, which is an 
indication that there was iron repletion despite abnormal 
haemoglobinisation. These patients are likely suffering from ACD or renal 
disease and, requiring erythropoietin treatment. Quadrant B represents 
normal RET-He and normal HB. These patients are part of the population who 
are not currently suffering from IDA or may have not begun iron deficient 
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erythropoiesis and, could have been recently treated. Patients within 
quadrant C were identified as having low RET-He and low HB, the majority of 
them had inflammation. These categories of patients were considered to 
have classic IDA and would require treatment. Quadrant D shows patients 
with low RET-He and normal HB in the presence of inflammation. This is 
where the real advantage of RET-He is seen. HB here is a late responder and 
failed to identify these patients. RET-He parameter was able to identify these 
patients with FID in the presence of inflammation.  
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   Figure 3.9: Plot for RBC-He (pg) versus HB (g/dL) in female patients with IDA     
Figure 3.9 above compared RBC-He with HB results in female patients with 
IDA in the presence or absence of inflammation. The essence was to see if 
RBC-He was a better diagnostic indicator to identify female patients with IDA 
in the presence of inflammation. Quadrant A represents female patients with 
normal RBC-He and low HB, which is an indication that there was iron 
repletion despite abnormal haemoglobinisation. Inflammation is also present 
in all the patients except one. These patients are likely suffering from ACD or 
renal disease requiring erythropoietin treatment. Quadrant B represents 
normal RBC-He and normal HB. These patients are part of the population 
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who are not suffering from IDA or may have not begun iron deficient 
erythropoiesis. Patients within quadrant C were identified as having low RBC-
He and low HB and majority of them had inflammation. The categories of 
patients were considered to have classic IDA and would require treatment. 
Quadrant D shows patients with low RBC-He and normal HB in the presence 
of inflammation. This is where the real advantage of RBC-He is seen. HB here 
is a late responder to iron deficiency and failed to identify these patients. 
RBC-He parameter was able to identify the patients with FID in the presence 
of inflammation.  
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        Figure 3.10: Plot for RET-He versus LogSF in female patient with IDA 
The diagnostic plot in Figure 3.10 above was used to assess the relationship 
between RET-He and SF with or without inflammation in female patients with 
IDA. Quadrant A shows patients with normal RET-He and low SF. Half of the 
patient population within this quadrant presents with inflammation, and 
could be classified as having ACD. Quadrant B shows patients with normal SF 
and normal RET-He, significant number of patients presented with 
inflammation. These patients are considered as part of the “normal” 
population who are not suffering from IDA or may have not begun iron 
deficiency erythropoiesis. Quadrant C represents the patients with low RET-
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He and low SF, these patients are most likely suffering from frank deficiency, 
and have not commenced treatment. Quadrant D shows patients with low 
RET-He and normal SF. These patients are considered as having classical IDA. 
The real advantage of RET-He is seen here, and the inflammation may have 
affected SF. 
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           Figure 3.11: Plot for sTfR versus LogSF in female patients with IDA 
Figure 3.11 as shown above was used to assess the diagnostic ability between 
sTfR and SF values in female patients with IDA. Quadrant A shows low SF and 
high sTfR. The sTfR levels have increased to utilise any available iron within 
the body. It could be suggested that these patients have IDA or ACD and have 
not yet started treatment. Quadrant B indicates high sTfR and normal SF, the 
patients may have been mis-diagnosed as having IDA. Quadrant C patients 
have low SF and high sTfR. Quadrant D shows normal sTfR and normal SF. 
This is a clear indication that, the use of sTfR in this group has not particularly 
provided additional information beyond the ability of SF to reflect low iron.  
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           Figure 3.12: Plot for HB versus sTfR in female patients with IDA  
Figure 3.12 above compared HB results with sTfR in female patients with IDA 
classification, and with or without inflammation. The essence was to see if 
sTfR could provide further information leading to the diagnosis of IDA at the 
early stage. Quadrant A indicates patients with low sTfR and normal HB with 
inflammation. Quadrant B shows patients with high sTfR and normal HB. 
Quadrant C indicating patients with low sTfR and low HB and quadrant D 
shows high sTfR and low HB. In all the quadrants, sTfR did not indicate female 
patients with IDA better than the HB has been able to do. It is apparent from 
the plot that sTfR did not particularly provide additional information in the 
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patient population, and appears to have not been influenced by 
inflammation.  
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   Figure 3.13: Plot for LogSF versus HB in the female patients with ID 
The diagnostic plot above was used to assess the relationship between SF 
and HB in the female patients with ID classification using cut-off point HB ≤ 
11.5 g/dL and ferritin ≤ 20 ng/mL. Quadrant A shows normal SF and low HB, 
this is a likely picture of an ACD. Even in the presence of full iron stores, HB 
level was low. Quadrant B indicates normal SF and normal HB. These are part 
of the “normal” population which shows no deficiency or are regarded as 
latent stage of ID. Quadrant C presents the characteristics of classical ID. It is 
universally acknowledged that SF is probably the best indicator of ID when it 
is low. This was indicated in Quadrants C and D. Quadrant D showing normal 
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HB clearly indicates that HB is a late responder, and would usually be the last 
indicator to become reduced. If inflammation is introduced, the case may 
become reversed, and SF could become unreliable. 
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           Figure 3.14: Plot for RET-HE versus LogSF in female patients with ID 
The diagnostic plot in Figure 3.14 above was used to assess the relationship 
between RET-He and SF in female patients with ID classification. Quadrant A 
shows patients with normal RET-He and low SF. These patients are believed 
to be suffering from ACD and, some of them may be responding to recent 
treatment. Quadrant B shows patients with normal RET-He and normal SF. 
These patients are considered as part of the “normal” population who are 
not suffering from ID or may have not begun iron deficiency erythropoiesis. 
Quadrant C represents the patients with low RET-He and low SF. These 
patients are most likely suffering from frank ID, and have not commenced 
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treatment. Quadrant D represents those with normal iron store and low RET-
He. These patients are considered to have classic ID, and this would indicate 
that SF result could be misleading. The real advantage of RET-He could is seen 
in this picture. 
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        Figure 3.15: Plot for RBC-He versus LogSF in female patients with ID  
The diagnostic plot in Figure 3.15 above was used to assess the relationship 
between RBC-He and SF in female patients with ID. Quadrant A shows 
patients with normal RBC-He and low SF, patients are believed to be suffering 
from ACD, and some of them may have been treated. Quadrant B shows 
patients with normal RBC-He and normal SF. These patients are considered as 
part of the “normal” population who are not suffering from IDA or may have 
not begun iron deficiency erythropoiesis. Quadrant C represents patients 
with low RBC-He and low SF. These patients are most likely suffering from 
classic ID, and have not commenced treatment. Quadrant D shows patients 
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with low RBC-He and normal SF. These patients are considered as having 
classical IDA. The real advantage of RBC-He is seen here.  
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        Figure 3.16: Plot for LogSF versus sTfR in female patients with ID  
Figure 3.16 as shown above indicates the population of female patients with 
ID classification. Quadrant A shows normal sTfR and normal SF. Quadrant B 
indicates normal SF and high sTfR, these patients may have been mis-
diagnosed as having ID. Quadrant C shows low SF and normal sTfR, it could be 
suggested that these patients have ACD and, have not yet started treatment. 
They are probably still relying on sTfR to improve this deficiency.  Also, 
because of the likely inflammatory states and other conditions as indicated 
by ZPP > 70 µmolezp/mole haem, the majority of the patients in Quadrant C 
may have iron that is in the reticulo-endothelial storage and, not being 
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released for erythropoiesis. The outcome is that the transferrin bound iron, 
which is reflected by sTfR, becomes low on occasion. Quadrant D patients 
have low SF and high sTfR. It is interesting to see how many of the patients 
had elevated ZPP. 
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          Figure 3.17: Plot for RET-He versus sTfR in female patients with ID  
The plot in Figure 3.17 above shows the diagnostic ability of RET-He in 
comparison to sTfR in female patients with ID. Quadrant A shows normal 
RET-He and normal sTfR and the majority of the patients had inflammation. 
Quadrant B indicates normal RET-He and high sTfR. Quadrant C shows low 
RET-He and normal sTfR, it could be suggested that these patients have IDA 
or ACD, and have not yet started treatment, as they are still relying on sTfR to 
improve this deficiency.  The majority of the patients in Quadrant C may have 
iron that is in reticulo-endothelial storage and, are not released for 
erythropoiesis. The outcome is that, the transferrin bound iron, which is 
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reflected by sTfR, becomes low on occasion. In quadrant D patients have low 
RET-He and high sTfR, this indicate classical ID and, patients would require 
treatment. The measurements of RET-He provide useful information in the 
diagnosis of FID with inflammation. sTfR does not get affected in 
inflammation, the majority of  patients who had normal haemoglobinisation 
also presented with inflammation.  
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Table 3.5: Haematological and biochemical characteristics for 31 normal subjects 
and 271 male patients. 
 
Parameters Normal subjects  
Range (Mean) 
 
Iron deficient  
Ranges (Mean) 
 
Reference  
Ranges used 
Haemoglobin  
(g/dL) 
14.2 – 13.7 (13.7) 6.80 – 19.6 (12.4) 13.5 – 18.0 
Mean cell volume 
(fl) 
83.2 – 100.3 (94.8) 66.0 – 109 .0 (88.1) 76.0 – 100.0 
MCH (pg) 27.4 – 35.8 (33.2) 18.0 – 38.0 (29.6) 27.0 – 33.0 
MCHC (g/dL) 29.2 – 34.2 (32.1) 20.3 – 37.0 (31.8) 31.0 – 35.0 
RDW (%) 12.2 – 18.5 (16.1) 11.8 – 27.0 (15.2) 11.5 – 14.5 
RET-He  (pg) 27.9 – 38.1 (30.4) 15.0 – 39.9 (26.5) 23.0 – 32.0 
RBC-He (pg) 28.2 – 36.5 (31.5) 18.0 – 37.0 (26.7) 23.0 – 32.0 
ZPP (µmole zp/mole 
haem) 
48.0 – 122.4 (69.3) 18.0 – 450 (74.4) 60.0 – 80.0 
Ferritin (ng/mL) 27.3 – 488.0 (96.7) 2.8 – 1489.3 (85.4) 12.0 – 300 
Iron (µmol/L) 21.0 – 72.1 (54.3) 1.3 – 67.4 (12.3) 11.6 – 30.0 
sTfR (mg/L) 13.2 – 29.1 (19.5) 2.3 – 102.2 (23.8) 8.7 – 28.0 
sTfR Index 6.8 – 19.6 (16.3) 1.8 – 292.0 (18.8) 12.0 – 14.5 
 
Table 3.5 above presents the overall descriptive data obtained for the 
haematological and biochemical parameters measured in the 31 normal 
subjects, 271 male patient samples and the corresponding reference ranges 
used. Using the criteria described in section 3.5 patients were classified into 
iron deficient, IDA and normal. 
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   Figure 3.18: Box plot showing the iron indices in male population with ID 
The box and whisker plots presented in Figure 3.18 above were used to 
present the preliminary data spread of the individual iron parameter versus 
ID status in the male patient population and, to indicate the potential value 
of individual parameters. The bottom and the top of each box represent 
lower and upper quartiles (25th and 75th percentiles respectively). The 
horizontal line inside the box is the median value (50th percentile) for the 
data distribution for each parameter presented in the plot. The whiskers at 
both ends of the box represent the minimum and maximum (5th and 95th 
percentile) of all data. Data not included are shown as stars and are known as 
outliers. The distribution for both RET-He and RBC-He are fairly symmetrical 
as the ‘Box’ sits in the middle of the range of values for both ID (Present) and 
ID (Not Present). HB was negatively skewed and, the median is grouped to 
the left in the negative direction. MCH was positively skewed. Based on the 
spread in the Figure 3.18 above, the preliminary display indicates no distinct 
identification of ID using MCV, HB, LOGFERR and MCH. The reason could be 
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as a result of some factors which could have possibly resulted in the 
overlapping of results. However, the aggregate in the box plots indicates that 
RET-He and RBC-He could potentially help to identify ID in comparison to the 
other indices. 
 
 
                  Figure 3.19: Box plot showing the iron indices in male population with IDA 
The box and whisker plots presented in Figure 3.19 above were used to 
present the preliminary data of iron indices distribution versus IDA status in 
the male patient population and, to indicate the potential value of individual 
parameters. The bottom and the top of each box represent lower and upper 
quartiles (25th and 75th percentiles respectively). The horizontal line inside 
the box is the median value (50th percentile) for the data distribution for 
individual parameter. The whiskers at both ends of the box represent the 
minimum and maximum (5th and 95th percentile) of all data. Data not 
included are shown as stars and are known as outliers. The data distribution 
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for both RET-He and RBC-He seem fairly symmetric as the ‘Box’ sits in the 
middle of the range of values for both IDA (Present) and IDA (Absent), and 
the whiskers are approximately equal in length. HB is negatively skewed and, 
the median is grouped to the left in the negative direction. MCH is also 
positively skewed. The aggregate in the box plots indicates that RET-He and 
RBC-He could potentially identify IDA. Likewise, HB and MCV appear 
promising.  
A receiver-operator characteristics (ROC) curve was constructed by reference 
to the set criteria for classifying patients into either ID or IDA for the 271 
male patients, and determining the inflammation status of the patients using 
CRP levels. 
The first ROC curve constructed, as shown in Figure 3.20 below was for male 
with IDA classification. HB ≤ 13.5 g/dL was chosen as the value most suited 
and close to the highest sensitivity for distinguishing IDA.  
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 Figure 3.20:  ROC curve for the male patients with IDA classification using HB ≤ 13.5. 
The ROC curve shown in Figure 3.20 above was for male patients with IDA. A 
cut-off point of HB ≤ 13.5 g/dL was chosen as the value most suited and close 
to the highest sensitivity for distinguishing IDA.  
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Table 3.6: AUCROC, sensitivity and specificity for iron indices                                                            
in male with IDA 
Parameters Cut-off 
Point 
AUCROC Sensitivity 
% 
Specificity 
% 
HB (g/dL) ≤ 13.5 0.99 100.0 99.9 
MCV (fl) < 80 0.98 96.0 94.0 
RET-HE (pg) ≤ 28 0.89 88.6 83.0 
RBC-HE (pg) ≤ 28 0.87 83.8 80.0 
ZPP (µmole zp/mole 
haem) 
≤ 70 0.35 60.0 81.4 
SF (ng/mL) ≤ 20 0.82 80.0 64.0 
 
Tables 3.6 above present the sensitivity and specificity of each parameter. HB < 
13.5 g/dL was chosen to classify male patient as having IDA. The diagnostic 
performances of RET-He and RBC-He in IDA were compared with the 
traditional parameters. By using RET-He < 28 pg, IDA in male patients within 
this study could be diagnosed with a sensitivity of 88.6% and a specificity of 
83.0%. Also, using a cut-off level RBC-He < 28 pg, IDA in male patients group 
could be diagnosed with a sensitivity of 83.8% and a specificity of 80.0%. The 
AUC for HB was 0.99 and, has a sensitivity of 100% and a specificity of 99.9% to 
identify male patients with IDA.   
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             Figure 3.21: ROC for male patients with ID classification with SF≤ 20 ng/mL 
The ROC curve constructed, as shown in Figure 3.21 was for male patients 
with ID. SF ≤ 20 ng/mL was chosen as the cut-off point most suited and close 
to the highest sensitivity for distinguishing ID.  
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               Table 3.7: AUCROC, sensitivity and specificity for iron indicators in male with ID 
 
 
 
 
 
 
Tables 3.7 above present the sensitivity and specificity of each parameter of 
iron indices. SF ≤ 20 ng/mL was chosen to classify patient as ID. Hence, the 
strong ability of SF in identifying ID. The diagnostic performances of RET-He 
and RBC-He in ID were compared with the traditional parameters of ID. By 
using a cut-off of RET-He ≤ 28 pg, ID in male patients could be diagnosed with 
a sensitivity of 78.4% and a specificity of 66.0%. Also, using cut-off level RBC-
He ≤ 28 pg, ID could be diagnosed with the sensitivity of 80.0% and a 
specificity of 61.2%. The AUC for SF was 0.99 and, has 100.0% sensitive and 
specificity. HB has a sensitivity of 82.8% and a specificity of 81.6% ability to 
identify male patients with ID. In inflammatory condition, the sensitivity and 
specificity of SF may become unreliable, this is where the real advantage of 
RET-He and RBC-He would be seen. 
Parameters  Cut-off 
Point 
AUCROC Sensitivity 
% 
Specificity 
% 
 HB (g/dL) ≤ 11.5 0.84 82.8 81.6 
MCV (fl) < 80 0.82 42.2 92.3 
RET-HE (pg) ≤ 28 0.78 78.4 66.0 
RBC-HE (pg) ≤ 28 0.79 80.0 61.2 
ZPP(µmole zp/mole 
haem) 
≤ 70 0.34 48.4 28.0 
SF (ng/mL) ≤ 20 1.00 100.0 100.0 
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3.8  Assessment of iron indicators in male patients 
To assess the diagnostic relationship between the biochemical and 
haematological parameters, the following diagnostic plots were used to 
indicate the ability of the individual parameters measured to correctly classify 
271 male patients with ID and IDA in the presence of inflammation. 
Parameters were also examined and plotted using the appropriate cut-off 
values to evaluate individual ability in iron status evaluation. 
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Figure 3.22: Plot for RBC-He versus LogSF in male patients with ID  
The diagnostic plot in Figure 3.22 above was used to assess the relationship 
between RBC-He and SF in male patients with ID. Quadrant A shows patients 
with normal RBC-He and low SF, patients are believed to be suffering from 
ACD and some of them may have been treated. Quadrant B shows patients 
with normal RBC-He and normal SF. These patients are considered as part of 
the “normal” population who are not suffering from ID or may have not 
begun iron deficiency erythropoiesis. Quadrant C represents the patients 
with low RBC-He and low SF. These patients are most likely suffering from 
classic ID and, have not commenced treatment. Quadrant D shows patients 
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with low RBC-He and normal SF. These patients are considered as having 
classic ID. The real advantage of RBC-He is seen here.  
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     Figure 3.23: Plot for RET-He versus sTfR in male patients with IDA 
The plot above (Figure 3.23) shows the diagnostic ability of RET-He in 
comparison to sTfR. Quadrant A shows normal sTfR and normal RET-He and 
the majority of the patients had inflammation. Quadrant B indicates high sTfR 
and normal RET-He. Quadrant C shows low RET-He and normal sTfR, it could 
be suggested that these patients have IDA or ACD and, have not yet started 
treatment, as they are still relying on sTfR to improve the deficiency. The 
majority of patients in Quadrant C may still have iron in the reticulo-
endothelial storage, and not being released for erythropoiesis. The outcome 
is that the transferrin bound iron, which is reflected by sTfR, becomes low on 
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occasion. In quadrant D patients have low RET-He and high sTfR, which 
indicate classic ID and the patients, would require treatment. The 
measurements of RET-He provide useful information in the diagnosis of FID 
with inflammation. sTfR does not get affected in inflammation, the majority 
of the patients who had normal haemoglobinisation were also presented 
with inflammation.  
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Figure 3.24: Plot for RET-He versus Log SF in male patients with ID  
The diagnostic plot in Figure 3.24 above was used to assess the relationship 
between RET-He and SF in male ID. Quadrant A shows patients with normal 
RET-He and low SF. Quadrant B shows patients with normal SF and normal 
RET-He. These patients are considered as part of the “normal” population 
who are not suffering from ID or may have not begun iron deficiency 
erythropoiesis. Quadrant C represents the patients with low RET-He and low 
SF, these patients are most likely suffering from frank iron deficiency and, 
have not commenced treatment. Quadrant D shows patients with low RET-
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He and normal SF. These patients are considered as having classical ID. The 
real advantage of RET-He is seen here. 
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                                       Figure 3.25: Plot for RET-He versus sTfR in male patients with ID  
The plot above shows the diagnostic ability of RET-He versus sTfR. Quadrant 
A shows normal RET-He and normal sTfR, the majority of the patients had 
low ZPP. Quadrant B indicates normal RET-He and high sTfR. Quadrant C 
shows low RET-He and normal sTfR, it could be suggested that these patients 
have IDA or ACD, and have not yet started treatment, as they are still relying 
on sTfR to improve this deficiency.  In quadrant D, patients have low RET-He 
and high sTfR, which indicate classic ID in this population. The measurements 
of RET-He provide useful information in the diagnosis of FID. sTfR does not 
get affected in inflammation, the majority of the patients who had normal 
haemoglobinisation also have ZPP < 70 µmole zp/mole haem. The usefulness 
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of the RET-He depends on how good it was at predicting the elevated sTfR 
values. 
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Figure 3.26: Plot for RET-He versus HB in male patient with ID classification 
Figure 3.26 above compared RET-He with HB in male patients with ID 
classification. Quadrant A represent male patients with normal RET-He and 
low HB, these patients are likely suffering from ACD or renal disease requiring 
erythropoietin treatment. Quadrant B represent normal RET-HE and normal 
HB. These patients are part of the population who are not currently suffering 
from ID or may have not begun iron deficient erythropoiesis or have been 
recently treated. Patients within quadrant C were identified as having low 
RET-He and low HB. The categories of patients were considered to have 
classic ID and would require treatment. Quadrant D shows patients with low 
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RET-He and normal HB. This is where the real advantage of RET-He is seen. 
HB here is a late responder to iron deficiency and failed to identify these 
patients. RET-He parameter was able to identify the patients with FID.  
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                                          Figure 3.27: Plot for RBC-He versus HB in male patients with ID    
Figure 3.27 above compared RBC-He results in male patients with ID 
classification with HB. Quadrant A represents male patients with normal RBC-
He and low HB, which is an indication that, there is iron repletion with 
decreased HB of red cells. These patients are likely suffering from ACD or 
renal disease requiring erythropoietin treatment. Quadrant B represents 
normal RBC-He and normal HB. These patients are part of the population 
who are not currently suffering from ID or may have not begun iron deficient 
erythropoiesis or have been recently treated. Patients within quadrant C 
were identified as having low RBC-He and low HB. The categories of patients 
were considered to have classic ID and would require treatment. Quadrant D 
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shows patients with low RBC-He and normal HB. This is where the real 
advantage of RBC-He is seen. HB here is a late responder to iron deficiency 
and failed to identify these patients.  
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Figure 3.28: Plot for RBC-He versus HB in male patients with IDA classification. 
 
Figure 3.28 above compared RBC-He results in male patients with IDA 
classification with HB. Quadrant A represents male patients with normal RBC-
He and low HB, which is an indication that, there is iron repletion with 
decreased HB of red cells. These patients are likely suffering from ACD or 
renal disease requiring erythropoietin treatment. Quadrant B represents 
normal RBC-He and normal HB. These patients are part of the population 
who are not currently suffering from IDA or may have not begun iron 
deficient erythropoiesis or have been recently treated. Quadrant C patients 
have low RBC-He and low HB. The categories of patients were considered to 
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have classic IDA and would require treatment. Quadrant D shows patients 
with low RBC-He and normal HB. This is where the real advantage of RET-He 
is seen.  
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Figure 3.29: Diagnostic plot for RET-He versus HB in male patients with IDA 
classification. 
Figure 3.29 above compared RET-HE results in male patients with IDA 
classification with HB. Quadrant A represents male patients with normal RET-
He and low HB, which is an indication of iron repletion with decreased HB of 
red cells. These patients are likely suffering from ACD or renal disease 
requiring erythropoietin treatment. Quadrant B represent normal RET-HE and 
normal HB. These patients are part of the population who are not currently 
suffering from IDA or may have not begun iron deficient erythropoiesis or 
have been recently treated. Patients within quadrant C were identified as 
having low RET-He and low HB. These patients were considered to have 
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classic IDA and would require treatment. Quadrant D shows patients with low 
RET-He and normal HB. This is where the real advantage of RET-He is seen. 
HB here is a late responder to iron deficiency and failed to identify these 
patients. RET-He parameter was able to identify the patients with FID.  
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3.9  Haemochromatosis patients 
Traditionally, SF and transferrin saturation have been used to diagnose 
patients with haemochromatosis. SF correlates well with body iron stores, 
and an elevated level of SF has been known to have a sensitivity of 80% and 
specificity of 90% in the diagnosis. Genetic screening has been widely used to 
define further genotypically the familial occurrence of iron overload 
associated with C282Y homozygosity or C282Y/H63D compound 
heterozygosity (Bacon et al., 1999). One hundred samples were received 
from haemochromatosis patients currently undergoing treatment. There was 
no particular attempt to identify complications as a result of iron overload. 
However, there were patients with associated conditions like diabetes 
mellitus and liver cirrhosis. These conditions have been known to be more 
frequent in C282Y/C282Y than in other pro-bands of haemochromatosis 
(Sham et al., 1997). The aim was to assess the usefulness of RET-He and RBC-
He in comparison with HB, HCT and MCV. The RET-He and RBC-He were 
measured in addition to FBC to determine if both indices could provide the 
same or improved information when compared with HB and HCT in the 
patients.  
Tables 3.10 and 3.11 below present data obtained from 100 specimens 
received from haemochromatosis patients during treatment. All participants 
were white, and the mean age of all persons was 48 ± 15 years (range, 32 – 
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66 years). 49 (49%) were male, and 51 (51%) were female.  There was no 
significant different in age between men and women.  
 
  Table 3.8:  Haemochromatosis data - Male patients on treatment  
Parameters Range      Male  
(n = 49) 
Agreement with RET-He & 
RBC-He 
RBC (106µL) 3.88-6.35 100% 
HB (g/dL) 14.4.0-19.8 99% 
HCT (%) 0.39-0.60 99% 
MCV (fL) 74.2-108.4 99% 
MCH (pg) 24.4-37.4 99% 
MCHC (g/dL) 34.6-37.2 100% 
RET-He (pg) 25.0-41.6 99% 
RBC-He (pg) 22.2-38.3 99% 
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            Table 3.9: Haemochromatosis patients – Female patients on treatment 
Parameters Range Female  
(n = 51) 
Agreement with RET-He & RBC-
He 
RBC (106µL) 3.24-5.94 100% 
HB (g/dL) 13.2-17.5 99% 
HCT (%) 0.32-0.55 99% 
MCV (fL) 71.2-103.7 99% 
MCH (pg) 23.5-35.4 99% 
MCHC (g/dL) 33.8-37.0 100% 
RET-He (pg) 24.0-40.6 99% 
RBC-He (pg) 21.2-37.5 99% 
 
Patients within this category were the subjects of treatment. The mainstay of 
treatment for haemochromatosis remains phlebotomy. In most cases, a unit 
of blood (equal to 250 mg of iron), depending on the haematocrit, were 
removed per week.  
The parameters presented in Table 3.8 and 3.9 were measured after the 
phlebotomy had taken place during one of the treatment visits. Male patients 
had significantly greater values of RBCs, HB and HCT than female. RBC (male 
vs female) 3.88-6.35 x 106µL vs 3.24-5.94 x 106µL; HB (male vs female) 14.4-
19.8 g/dL vs 13.2-17.5 g/dL; HCT (male vs female) 0.39-0.60 vs 0.32-0.55% 
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with P < 0.001 for each comparison. MCV was greater in males than for 
females (74.2-108.4 fL vs 71.2-103.7 fL with P = 0.02). MCH and MCHC were 
marginally higher in males than in females (24.5-37.4 pg vs 23.5-36.6 pg; 
34.6-37.2 g/dL vs 34.6-37.2 g/dL; P = 0.02) respectively. However, values of 
RET-He and RBC-He were 99% in agreement when considered alongside HB, 
HCT and even the MCV values in both males and females (RET-He 25.0-41.6 
pg vs 24.0-40.6 pg and 22.2-38.3 pg vs 21.2-37.5 pg). Only one out of 51 
samples analysed in the female category, had a reduced RET-He and RBC-He 
where the HB and HCT were high. The data shown in Tables 3.8 and 3.9 
indicates the relative correlation between RET-He, RBC-He and HB, HCT and 
MCV.   
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CHAPTER 4   DISCUSSION 
 
In recent years, many of the published articles on ID have discussed areas 
ranging from screening the healthy individual to diagnosis and prevention. 
More importantly, many workers have spent time considering the diagnosis 
of iron restricted erythropoiesis to overload in various stages of disease in 
different populations. However, the possibility that RET-He and RBC-He 
indices can be used in the early detection of ID in a larger population of 
young and adults, in conjunction with other haematological parameters 
without the need to rely solely on the traditional use of biochemical analysis, 
has not been fully investigated.  
One of the recommendations put forward in the report of a joint World 
Health Organisation/Centre for Disease Control and Prevention on the 
assessment of iron status at the population level was that an additional study 
was needed to validate the recommended indicators of iron status (World 
Health Organisation, 2004, p94).  
Ullrich et al., (2005) demonstrated that RET-He should be the preferred 
screening tool in the early detection of ID and recommended further studies 
to validate this claim. A review article published by Wish (2006), highlighted 
the need to weigh the benefits of other tests that may prove useful when 
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screening for ID especially in challenging cases, rather than the use of the 
traditional markers (Wish, 2006), 
The accurate and early diagnosis of IDA is essential because it might be the 
first presenting sign of occult bleeding associated with possible malignancies 
(Willoughby & Laitner, 2000). In the patient group, RET-He provides a 
snapshot of recent functional availability of iron to the erythrocyte. This 
group of patients appears to have normal RET-He values, and yet low SF 
which would indicate that they have recently started treatment for ID. RET-
He represents the last 48 h of erythrocyte activity. If the patient is on iron 
supplements, this would not have been affected. However, the iron stores 
will take longer to return to normal, so continued iron treatment is necessary 
to see a return to normal SF values. Intuitively, combining multiple iron status 
indicators provides the best assessment of iron. Therefore, the combination 
of HB, MCV, RET-He and RBC-He would provide better diagnosis and guide 
treatment of ID.  
Many studies have also been performed in relation to the use of RET-He and 
RBC-He, but not in a similar patient population as in this study. The majority 
of the studies have focussed on patients undergoing chronic haemodialysis, 
and some other cases where iron therapy was required. Two studies 
examined the clinical utility of the reticulocyte index (CHr) using the Siemens 
Advia 120 and 2120, with comparison to other markers of ID. They reported 
slightly different cut-off values as the optimal CHr cut-off (26.0 and 27.5 pg) 
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in both studies (Brugnara, et al., 1999; Ullrich et al., 2005). Also, when the 
Sysmex XE2100 was introduced to the haematology laboratory, two groups 
investigated the potential benefits of identifying FID using RET-He. The 
findings reported that RET-He had a close correlation (in relation) to CHr, sTfR 
and % hypochromic red cells, as they were known on the ADVIA 120, and the 
understanding was that RET-He could be an acceptable parameter for 
indicating FID (Briggs et al., 2001; Thomas & Thomas, 2002). CHr has also 
been useful in differentiating anaemia and, in monitoring erythropoietin 
therapy in renal patients undergoing dialysis, the sensitivity was good for 
detecting relative ID in this study, with a false positive of 20% (specificity 
80%) (Briggs et al., 2001; Thomas & Thomas, 2002). The study carried out by 
Luo et al., (2007), compared the diagnostic efficacy of CHr to other markers 
of ID in Chinese premenopausal women. They recommended further studies 
to determine whether CHr should be the preferred screening tool in the early 
detection of ID in larger population of pre-menopausal women and children. 
Although studies examining the diagnostic usefulness of various 
haematological and biochemical parameters have been undertaken, no study 
of iron status in inflammation has so far included measurements of MCV, SF, 
MCH, RDW, ZPP, Fe, sTfR, RBC-He and RET-He indices. This study has 
incorporated all the haematological and biochemical iron indicators and 
included RET-He and RBC-He as part of the FBC to see if they could provide 
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additional information on iron status in patients with chronic disease and 
inflammation. 
The results described in this thesis examined the potential value of the 
currently used haematological screening tests for detecting ID, and compared 
them with RET-He and RBC-He. Both parameters were found to be useful in 
the assessment of iron status within the population studied, when 
considered alongside the traditional markers of ID including SF and sTfR. 
It was necessary early in the study to determine the stability of RET-He and 
RBC-He. This was performed to determine if the parameters would be stable 
over time, especially when samples arrive late into the laboratory and the 
analysis is delayed. All the 15 samples were measured for RET-He, RBC-He, 
HB and MCV, following storage at room temperature, 4oC, 20oC and 30oC 
over a period of 4 days. Acceptable readings were recorded for all the 
parameters except MCV. MCV became unstable shortly after 24 h. This 
effectively limits its diagnostic utility, because results obtained from 
prolonged or delayed analysis proved MCV values could change dramatically 
from being very low to becoming normal in patients with ID. This could 
potentially misguide physicians if they rely on the MCV in the diagnosis of ID.  
It is useful to know that there were no significant changes in samples 
analysed when stored over 96 h for RET-He and RBC-He measurement, 
indicating good stability. Therefore, any delay in sample receipt may not 
affect the results of RET-He and RBC-He indices. 
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Reproducibility results for RET-He and RBC-He for within-run and between-
run replicate analyses gave an agreement with the manufacturer’s 
specification. The total imprecision was excellent for RET-He (SD 0.82 pg, CV 
2.85%); and for RBC-He (SD 0.30, CV 1.24%). 
The understanding that iron status can be evaluated by the measurement of 
iron stores and circulating iron has been known for many years. However, SF 
and HB may not provide the conclusive answers due to their variability and 
insensitivity, especially in the presence of inflammation. The imbalance 
between iron needed by the marrow and the iron supply leads to a reduction 
of red cell haemoglobinisation. The outcome is hypochromic and microcytic 
anaemia, which is seen in FID. However, because SF may not accurately 
reflect FID in situations like this, the determination of the RET-He and RBC-He 
have been shown to provide useful information in diagnosing FID, and have 
indeed been offered as a possible alternative to the biochemical markers like 
iron, SF, transferrin and even sTfR (Brugnara et al., 1999; Cullen et al., 1999; 
Fishbane et al., 1997; Thomas & Thomas, 2002). Also, many of these studies 
have indicated that biochemical markers of ID are of limited value when 
assessing ID and FID, and they recommend further studies to assess RET-He 
and to use different cut-off values. One such study defined FID as a CHr < 28 
pg, which was based on the distribution obtained within the healthy 
population studied (Thomas & Thomas, 2002). Another study indicated that 
the CHr index will achieve 100% sensitivity when a cut-off is set at 32 pg for 
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ID (Mitsuiki et al., 2003). Others have suggested that the combined use of 
sTfR and SF provide better information in chronic inflammation (Benguin, 
2003; Bultink et al., 2001).  
In line with the limitations of the widely used iron status indicators, hepcidin, 
which is a key regulatory protein in iron metabolism and which acts by down-
regulating the release of iron from the duodenum and macrophage, could be 
a useful marker of iron status (Nemeth, 2004). Reduced serum hepcidin may 
enable an assessment of iron requirements and provide information 
regarding the physiological iron deficiency (Kemna et al., 2008). Recently, the 
quantitation of serum and urine hepcidin have been developed using mass 
spectrophotometry and immunoassay (Koliaraki et al., 2009). The clinical 
utility of hepcidin has been associated with the diagnosis of ACD, chronic 
kidney disease and haemochromatosis (Koliaraki et al., 2009). However, how 
much information it would add to the existing repertoire of iron is yet to be 
understood. Various studies have shown a good correlation between serum 
hepcidin and ferritin, indicating elevated levels for both assays in 
inflammatory disease (Pidgeon, et al., 2001). However, serum hepcidin has 
an advantage over ferritin, because of its ability to directly indicate the 
available need of iron in erythropoiesis. The role of serum hepcidin in relation 
to RET-He and RBC-He in the assessment of iron status is still not fully 
understood and would require further investigation. The main shortcoming 
of serum hepcidin when benchmarked against RET-He and RBC-He is that the 
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assay has not been fully validated. Some workers found hepcidin level to 
correlate with CRP, as a marker of inflammation (Peter et al., 2010; Ford et 
al., 2010). Recently, hepcidin levels were found to predict erythropoietic 
response to an intravenous iron in haemodialysis patients (Tessitore et al., 
2010).However, the serum hepcidin assay is not routinely available for use in 
most laboratories, while RET-He and RBC-He are available on most 
haematology analysers and, if utilised appropriately, their values would 
contribute to the assessment of iron status. 
 In response to the literature, this study was set up to assess and explore the 
views put forward by these workers, to determine if RET-He and RBC-He as 
key independent indicators could identify patients with IDA without the need 
for biochemical analysis. The results from this study showed some 
measurable outcome for RET-He and RBC-He parameters in patients with ID 
and IDA. The number of investigations carried out for the screening and 
diagnosis of patients with or without ID can be minimized, and focus given to 
the haematological investigations of the red cell and erythrocyte 
haemoglobinisation assessment. 
The criteria used for patient classification as having ID were based on the SF ≤ 
20 ng/mL, while HB ≤ 11.5 g/dL for female and ≤ 13.5 g/dL for male was used 
to indicate patients with IDA. These are in agreement with the published data 
for SF and sTfR (Vernet & Doyen, 2000; Mast et al., 1998).  The cut-off value 
used for both RET-He and RBC-He was ≥ 28 pg. This value is in agreement 
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with the study conducted with the published data for RET-He (Thomas & 
Thomas, 2002). 
The first report of this study considered the analysis of 89 healthy individuals 
without inflammation showed that RET-He and RBC-He values ≥ 28 pg would 
indicate iron sufficiency. This is in agreement with other published data 
which quoted CHr < 28 pg as indicating FID (Mittman et al., 1997), and a CHr 
< 26 pg assumed to indicate ID as quoted elsewhere (Fishbane et al., 1997). 
This presents an understanding that normal haemoglobinisation means 
normal iron, but that was not the case in the results obtained for iron index 
in the normal population in this study. These indicated that, if serum iron 
were to be used as the key indicator of ID, many of the participants within 
the normal group would have been classified as having ID.  
The diagnostic plots used in this study have several advantages over other 
diagnostic diagrams. This is because different stages of ID can be identified at 
quick glance, and a combination of biochemical and haematological 
parameters can reveal early and progressive ID.  
The data in this group represents the population of hospitalised patients with 
anaemia, rheumatoid arthritis, gastroenteritis, cancer and renal disease at St 
James’s Hospital, Dublin. Because of the mixed diagnoses, and possible 
existence of various stages of ID, it was difficult to provide stratification for 
each disease. So as to avoid any sort of bias in the sample selection, analysis 
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and reporting, the diagnostic plot was used to classify patients based on the 
results of the traditional markers of iron, that is SF for ID and HB for IDA, 
which were used to classify patients into two, either as iron deficient or non 
iron deficient.  
Because iron metabolism is a dynamic process and cannot be defined by one 
or even two biochemical and haematological parameters, it is important to 
have a complete work-up based on a combination of profiles. Therefore, the 
assessment of the relationship between the currently used serum SF, 
haemoglobin versus RBC-He and RBC-He would be important. From this 
study, the initial assessment shows that RET-He and RBC-He indices could 
provide improved information over SF, and performed better than HB. SF 
concentrations were elevated in many of the male and female patients, 
possibly as a result of inflammation as indicated by CRP > 5mg/L.  This 
suggests that the SF concentration is unreliable in ID with systemic disease.  
Thomas et al, (2002) used a diagnostic plot, which was referred to as a 
‘Thomas plot’. The approach has been available to clinicians for the diagnosis 
of functional ID. This plot provides an excellent aid for differentiating 
functional ID from the classical ID. The Thomas plot was used in this study to 
evaluate results for RET-He, RBC-He with HB, if HB (cut-offs female < 11.5 
g/dL, and male < 13.5 g/dL) were used to indicate IDA, and when compared 
with RET-He and RBC-He. There was reasonable agreement as indicated in 
Figures 3.8, 3.10, 3.28 and 3.29. Kim et al. (2008) investigated the accuracy of 
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the content of haemoglobin in reticulocyte (CHr) in comparison with 
conventional tests, and the relationship between changes in CHr and HB level 
after treatment where CHr was found to be a better predictor to the 
response to anaemia treatment. From the diagnostic plots for both males and 
females in this study, the quadrants representing patient samples with low 
HB, and normal RET-He would indicate iron deficiency, but the fact that the 
RET-He is within the cut-off point defined, suggests that some of the patients 
have probably commenced treatment for ID. HB from the standard FBC 
sample represents the HB contents of all the erythrocytes which have a life 
span of 120 days. This means that it could possibly take at least 120 days for 
the HB value to return to the reference range. The patient samples within the 
quadrant represent the advantage of RET-He as a parameter useful in the 
monitoring of iron treatment. 
Some quadrants in the diagnostic plots showed correlation between normal 
RET-He and normal HB (Figures 3.8, 3.9, 3.26, 3.27, 3.28 and 3.29). The 
finding shows that these patients are part of the population which are not 
classed as iron deficient. Also, the quadrants representing patients with low 
HB and either low RET-He or low RBC-He (Figures 3.8, 3.9 and 3.28), indicates 
patients are most likely suffering from classic IDA, and are receiving no 
treatment as yet, hence the reason for the low RET-He. A low RET-He result 
with normal HB would indicate the very early stages of ID development 
where the bone marrow is just becoming affected. Although few patients 
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presented within these quadrants, this combination of result is not 
impossible and, if recognised, could provide huge advantages for the patient 
as treatment could be initiated as soon as possible.  
To compare RET-He, RBC-He with sTfR, as shown in Figures 3.11, 3.12 and 
3.17 in female patients, and Figures 3.23 and 3.25 in male patients, sTfR was 
particularly unaffected, which is suggestive of the relative insensitivity of sTfR 
in diagnosing FID. This is in agreement with the study of Briggs et al., (2001). 
Although sTfR has been described as having potential for the iron status 
evaluation (Punnonen et al., 1997), others have rejected the claim and 
recommend that the interpretation be made carefully, especially with 
erythroid marrow activity taken into consideration (Siebert et al., 2003). sTfR 
levels can be low in hypo-proliferative states, and is usually the last 
parameter to react to ID (Siebert et al., 2003). Although some patients 
appear to have a normal sTfR concentration, they may have low iron stores 
that could go unnoticed, if SF analysis is not performed. Therefore, it would 
appear that the use of sTfR is limited, and may only be useful in 
differentiating between ID and ACD (Siebert et al., 2003). sTfR can only be 
recommended as an additional parameter alongside the RET-He and RBC-He 
in the assessment of iron status. 
Tables 3.5 and 3.6 show the sensitivity and specificity of the parameters 
analysed. As indicated, when SF was used to classify patients as having ID in 
female patients, a sensitivity of 100.0% and specificity of 99.9% was achieved. 
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The issue of how much information can be provided by SF and HB depends 
on many factors, including age, gender and even ethnicity. The use of ZPP 
level is sensitive in the first line diagnostic test for IDA as during the depletion 
of iron, the utilisation of zinc increases and the resultant effect is seen in 
elevated ZPP (Das & Philip, 2008). Although many studies have reported that 
the ZPP increase compares well with the SF concentration < 20 ng/mL, 
findings in this study concur with that argument, even though it could 
potentially become elevated in chronic inflammation, which may limit its 
diagnostic ability (Hastka, et al., 1996). 
The ROC curve analysis as shown in Figures 3.5 and 3.6 for female patients, 
and Figures 3.20 and 3.21 for male patients, showed the AUCROC for RET-He 
and RBC-He to be as close as possible to the AUCROC for SF when it was 
chosen to classify ID, and also to HB when chosen to classify IDA in both 
female and male patients.  
Using SF as the standard indicator of ID in female patients, the AUCROC 
obtained for RET-He was 0.72, sensitivity was 89.6% and specificity was 
58.0%. The AUCROC for RBC-He was 0.72; sensitivity 88.6% and specificity 
57.0%. Regardless of the diagnosis, reticulocyte and erythrocyte indices allow 
haemoglobinisation of RBC changes to be monitored. This information gave 
an indication of its reliability and usefulness in the early prediction of iron 
status.  
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The study also considered MCV in relation to RET-He and RBC-He in the 
patient population. MCV is the average volume of the entire red cell 
population, and changes can take a relatively long time. It is recognised to be 
an insensitive measure of iron deficiency. From the stability study conducted 
within this project, MCV was indeed found to be unstable and this fact 
further limits its diagnostic potential. Also, some workers ranked MCH over 
MCV as a better marker of iron deficiency especially in patients with 
inflammatory diseases like rheumatoid arthritis. It was also found that many 
of the patients in this study presented with low MCH in comparison with 
MCV, which supports the view of O’Broin et al., (2005) in their proposal that 
MCH should be used in conjunction with SF in predicting IDA in patients with 
inflammatory disorder. 
Overall, the data in this study shows RET-He and RBC-He could provide an 
improved and early diagnosis of ID, providing a FBC sample is drawn in the 
first place, especially in non anaemic ID, when compared to HB, MCV, HCT, 
RDW, SF, and sTfR. The acute phase response questions the reliability of 
biochemical tests such as iron, TSAT and ZPP. SF in particular is a strong 
positive acute phase reactor and is substantially elevated in inflammatory 
conditions.  
It can be established from this study that the ability of the currently used 
traditional markers of iron status may be strengthened with the inclusion of 
RET-He and RBC-He. The correlation between RET-He and RBC-He in all 
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patient groups was excellent and are both interchangeable for diagnostic 
purposes.  
The understanding gained from this study indicates that RET-He and RBC-He 
could detect FID in various conditions. It is extremely important to establish a 
diagnosis in those patients with an inflammatory response, and the fact that 
RET-He and RBC-He provide the accurate number of individual red cells and 
reticulocyte analysis using the flow cytometry, is in contrast to MCV, MCH, 
MCHC which uses the calculation of the mean indices of the red cell, can be 
very insensitive as shown in this study. The reason is because, by the time the 
values of the MCV and MCH decline, the ID would have possibly progressed 
to an advanced stage on most occasions. Also, if this is accompanied by 
inflammation, measurement of SF and TSAT becomes unreliable. Therefore, 
the use of RET-He and RBC-He in an algorithm may improve accuracy of 
diagnosis without the need for additional costly tests. So for basic 
identification of ID, the author would recommend clinicians to request FBC, 
with the addition of RET-He and RBC-He in the profile. For complex diagnosis 
where inflammation is involved, the request for a FBC should include RET-He, 
RBC-He and ZPP. Separate serum samples should also be sent for sTfR and SF 
analysis. 
The work presented in this thesis identified useful diagnostic information that 
can be used in the frontline screening, diagnosis and monitoring of ID and FID 
in a mixed patient population.  
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Haemochromatosis treatment monitoring was also considered in this study 
using RET-He and RBC-He in comparison with RBC, HB, HCT, MCV, MCH and 
MCHC. The diagnosis of haemochromatosis can be made when a patient has 
an unexplained TSAT > 60% (male) and TSAT >50% (female), and this is 
supported by the measurement of SF concentration. The differential values 
obtained for males and females were significant in cases of RBC, HB and HCT. 
MCV and MCH were found to be sensitive in this study when compared with 
RBC-He and RET-He. It has also been claimed previously that an elevated 
MCV and microcytosis in haemochromatosis may be the result of liver 
disease. It has not been possible to verify this claim in this study because 
specific complications as a result of haemochromatosis were not considered 
within this study (Finch & Finch, 1955). However, the results obtained from 
the treatment monitoring shows all the erythrocytic parameters to be 99% or 
more sensitive when compared to RET-He and RBC-He in both males and 
females. Therefore, the possibility that RET-He and RBC-He could be useful in 
the monitoring of treatment of haemochromatosis patients exists. However, 
both parameters should be studied in pre and post phlebotomy treatment in 
the future. 
 
The author wishes to acknowledge the established guidelines for the 
diagnosis of ID that have been written and implemented by different working 
groups for clinical practice. The guideline, as provided for by the British 
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Society of Gastroenterologist in 2007, advised that most of the parameters 
within the study, such as haemoglobin, SF, and CRP should be used for 
laboratory screening. It was also recognised that, for patients in remission or 
with mid disease, at least one measurement of the parameter listed should 
be carried out every 6-12 months. The guideline also fully recognised that 
blood loss and chronic diseases could be a result of possible intestinal 
inflammation. Therefore, CRP and SF were added to the screening profile.  
The Inflammatory Bowel Disease working group, formed in 2005, decided on 
a guideline in 2007 which agreed that the interpretation of the iron indices 
should be based on modulating factors and should be based on an 
appropriate cut-off value. The screening parameters as agreed within the 
framework include the use of HB, SF and CRP. The approach introduced was 
that a full anaemia work up should commence once the HB level falls below 
the reference range. The anaemia workup as drawn up includes SF, sTfR, CRP, 
MCV and MCH. In screening for ID, the guideline provides for a SF level of < 
30 ug/L. A distinction was made that if the SF level is between 30 and 100 
ug/L, a diagnosis of anaemia of chronic disease (ACD) is likely, even though SF 
≤ 100 ug/L is the recommended cut-off. The author of this thesis would like 
to suggest the addition of RET-He and RBC-He to the guidelines, so as to 
provide adequate and correct diagnostic information which could be used to 
monitor therapeutic intervention especially in the category of patients who 
might have ID or ACD as a result of inflammation. 
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It was reported in the Ret-He White Paper, written and published by the 
Sysmex America, that the Kidney Disease Outcomes Quality Initiative recently 
updated its guidelines, which was driven by the complexities involved in the 
monitoring of ID associated with chronic kidney disease. The initiative 
recommended the use of RET-He with the threshold of 29 pg, rather than 
TSAT.  
Although this study did not directly involve clinicians, it does however 
provide information that would allow them to adequately care for their 
patients. For example, the Kidney Disease Outcomes Quality Initiative 
guidelines, published in 2006, caution the administration of iron when SF 
levels exceed 500 ng/mL. The reason is that the administration of iron could 
have a potential damaging effect on the treatment outcome. Many other 
issues relating to long-term safety and cost effectiveness have also been 
considered. Therefore, to avert the issue of assay reliability and its 
combination with sensitivity, ease of use and cost effectiveness, the inclusion 
of RET-He and RBC-He may provide some answers.  
It is also important to note that RET-He and RBC-He are not foolproof from 
limitations, part of it could be the widespread availability, which limit its use, 
especially in the developing countries and countries where it may be difficult 
to have the full complement of equipped haematology laboratories.  
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CHAPTER 5 CONCLUSION AND RECOMMENDATIONS 
 
5.0 Conclusions and implications for professional 
practice 
 
The findings in this study have explained the use of laboratory methods as an 
essential aspect of medicine. Although there is a myriad of laboratory tests 
and procedures available to clinicians, nowadays, it is not every laboratory 
test offered for a particular diagnostic investigation that will provide a 
definitive diagnosis. 
The work presented in this thesis concludes that the new reticulocyte and 
erythrocyte parameters RET-He and RBC-He are sensitive predictors of iron 
deficiency, and can be used to detect changes in cells with inadequate 
haemoglobinisation. RET-He and RBC-He will have a comfortable place in the 
screening, diagnosis, treatment and monitoring of iron status. It is suggested 
as well that the RET-He and RBC-He would be reliable in the evaluation of 
haemochromatosis patients who are currently undergoing treatment. 
However, because the study did not consider the complications that may be 
linked to haemochromatosis, the author wishes to propose the evaluation of 
RET-He and RBC-He in patients where complications have not occurred. Also, 
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more work could focus on pre and post iron depletion phlebotomy for 
comparison with the routinely used erythrocyte indices. 
The findings presented here have been implemented in the author’s 
laboratory, and are now available on a routine basis within the Haematology 
and Nutrition Laboratory of St James’s Hospital, Dublin, Ireland. 
The contribution of this study to the current awareness is to inform practice 
and also to indicate that interpretation of various biochemical and 
haematological indices should be done in the context of the clinical picture, 
because of the variability in the individual parameter which can make an 
assay unreliable when screening or diagnosing iron deficiency. 
Therefore, the use of RET-He and RBC-He in a diagnostic algorithm would 
improve accuracy of diagnosis of iron deficiency without the need for 
additional costly testing. So for basic identification of iron deficiency, the 
author would recommend clinicians to request FBC, with the addition of RET-
He and RBC-He in the profile. For complex diagnosis where inflammation is 
involved, the request for a full blood count should include RET-He, RBC-He, 
and ZPP. Separate serum should also be sent for sTfR and SF analysis. 
The main question emerging from this study would be to identify the 
implication of RET-He and RBC-He inclusion into the iron status investigation 
in practice. Given the fact that there have been several reports on the use of 
SF, transferrin saturation and sTfR in different diseases groups, it is important 
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to stress that no single test will exist without its own limitation, and 
therefore, RET-He and RBC-He are not fool-proof with 100% sensitivity and 
specificity. However, the findings conclude that both tests are highly 
sensitive. Also because the so called “gold standard” tests for iron deficiency, 
that is, SF and others, have serious limitations, the author can conclude that 
RET-He and RBC-He may serve as the closest parameters in reliably 
diagnosing ID. 
 
5.1  Change of practice 
The practicality and technicality of implementation of the findings in this 
study has provided some changes within the Haematology and Nutrition 
Laboratory of the hospital. Given the fact that the St James’s Hospital is the 
largest teaching hospital in Ireland, the real change tends to require a lot of 
things ranging from staff, cost and time, because of the overstretched 
workload. Therefore, the laboratory management would have to weigh the 
cost versus benefit of any new addition to the current service. Twenty 
percent of the FBC workload is received from general practice surgeries daily, 
and the total number received could be in the region of 3000 samples daily, 
including samples from within the hospital. In order not to add additional 
cost to the budgetary allocations for the laboratory, a decision was taken to 
write letters to all the GP surgeries which advised them of the availability of 
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the tests in the laboratory. This means if a request is needed, tests can be 
ordered within the test menu on the laboratory request. This will reduce the 
amount of reagents that would be needed to run the cytometric assays on 
every sample. The potential to run assays on every sample exists, but to 
avoid unnecessary cost, the priority is given to the requesters.  
 
5.2  Staff training 
Another consideration regarding the implementation of the outcome of this 
study will be hinged on staff training. The introduction of the RET-He and 
RBC-He to Sysmex XE2100TM analyser used in the Haematology Laboratory 
has not been difficult because the assays are available using the technology 
which is available on the existing analyser. The test is performed using the 
FBC sample, and in the same way of sample aspiration. The only changes to 
the operation are the reagent dyes required and the software modification. 
Therefore, the standard operating procedure will be written, and procedural 
amendment will be made, which will provide details of changes as part of the 
on-going training and education for staff.  
Also, because assays will be performed usually with a request for a FBC, it is 
envisaged that there would be no requirement for extra staff at this point in 
time. Hopefully, the addition of the test will fit well into the existing work 
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flow and will not have a negative impact on the turn-around time for the 
request. 
 
5.3 Transfer of the new tests to other laboratories in 
Ireland 
Most Irish laboratories (60%) have either ADVIA 120 or Sysmex XE2100 as the 
main haematological analyser. These analysers have potentials for measuring 
CHr, RET-He and RBC-He. ADVIA 120, which was the first haematology 
analyser used to measure CHr is very popular. Although many of the users do 
not utilise the feature on the analyser, with the outcome of this study, it is 
expected that laboratories will provide the test if requested by clinicians.  
 
5.4  Future investigations 
In order to examine the area of study further, it would be of interest to follow 
up requesting clinicians and patients, to study what impact the sole use of 
RET-He and RBC-He would have on the therapy if they rely on these indices 
for the iron status assessment.  
In order to establish the effective management of iron deficient patients, 
further work should be undertaken to develop an assessment tool that could 
be utilised post iron status assessment. 
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Whilst this study provides quantitative measurement of all the traditional 
markers of iron deficiency and the new markers, little is known about how 
clinicians intend to progress the new assays to help in the diagnosis and 
management, therefore, a qualitative study examining the clinicians pattern 
of request of iron indices may provide greater understanding of whether 
there would be a significant impact in the use of these tests. 
 
5.5  Publishing 
Throughout this project, the author has undertaken significant learning in 
relation to iron status and its assessment. This has led to local service 
improvement and an ongoing expansion of the test repertoire. In addition, 
the interim findings of this study have been presented at the national level of 
the Association of Clinical Biochemist in Ireland (ACBI) (Appendix C), and at 
the annual conference of the Academy of Medical Laboratory Science in 
Ireland (Appendix B). 
The overall findings of this study will produce at least one paper which will be 
submitted to the Annals of Clinical Biochemistry journal, and also to the 
British Journal of Biomedical Science. This would allow the findings to have 
more positive and wider impact on how iron status is assessed.  
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CHAPTER 6 REFLECTIONS ON PROFESSIONAL 
DOCTORATE 
 
Fish & Twinn (1997) believe competence in professional practice must 
embrace skills in new and developing aspects of that professional area. They 
also argued that today’s competence certainly may not be sufficient for 
tomorrow’s discoveries. Based on this and much evidence, learning is more 
likely to lead to an improvement in professional practice and development. 
It has been my ambition to pursue the medical laboratory profession to the 
highest level of qualification possible. As Eraut (1994) stated, ‘qualification is 
a rite of passage’ and a ‘landmark in the process of professional socialisation’. 
Even before I was accepted to study the professional doctorate, I had offers 
from two universities to study full time PhD by research in completely 
different aspects of science. Because the two offers were based on a full time 
study, I thought this would impact on my family and also my ability to 
continue to work. Therefore, I declined the offers. But because my goal was 
to focus on the biomedical science area, I became aware of the opportunity 
to study for a professional doctorate through reading the Biomedical 
Scientist.  
I live and work in the Republic of Ireland. This fact initially delayed the 
opportunity to meet with the programme manager, Professor Graham Mills. 
When I finally did in the summer of 2005, he was a little bit concerned about 
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the logistics involved in coming over to Portsmouth for class attendance, 
which was required to fulfil the Part 1 of the course. But I was so determined 
and, rather than visualising and analysing the problem with the logistics of 
travelling, I saw opportunity. It was indeed difficult, especially having to catch 
flights late at night and passing nights at a friend’s residence in Eastleigh to 
attend lectures the following morning. But I was glad when the two-weekly 
flights from Dublin to Southampton were over after two years.  
I enjoyed the Part 1 of the programme immensely. On reflection, the taught 
modules have developed my skills in research methods and analysis. I had 
opportunity to learn about things that I have never heard about. I found 
some aspects of the taught programme challenging but enjoyable. I met 
professionals from different backgrounds, and enjoyed the multidisciplinary 
interaction with colleagues. 
There is a huge difference between conducting research at master’s level and 
doctoral level, because of the complexities involved in designing and 
conducting research. I was able to build on the modules undertaken at Part I 
level and, sooner than I thought, with the help of my supervisor Dr Sean 
O’Broin, it dawned on me that I was on my own and that necessary planning 
was needed to get things done. I was mentally challenged, when it came to 
the point of writing the application to the ethics committee to be able to 
conduct the research. After many letters and meetings, I received an ethics 
approval to conduct the research, which was the first hurdle crossed to 
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succeed at this level of study. Overall, the understanding gained at the start 
of the course really helped me in writing a good proposal, and has 
enlightened my understanding on how to source funding, select patients, 
collect and analyse data. 
The stages of planning, reading, thinking, observing and setting up racks and 
ensuring samples get processed before certain times of the day are not fun at 
all. Especially when I was setting up the sTfR assays using the manual 
method. Perhaps that is the price you have to pay to undertake the doctoral 
research study. This is not to scare prospective applicants, but to prepare 
them for the challenges ahead. On reflection, I naturally gave up on many 
activities and found solace in staying late and working on the laboratory 
bench. 
Surely, I have always enjoyed working in the laboratory. I have been very 
fortunate to be able to work at the busiest and largest Hospital in Ireland, 
and the level of work carried out in the laboratory is rewarding. This afforded 
me the opportunity to be able to get my research work funded. I also had the 
opportunity to receive ideas from people with great experience in research 
and development whose support and encouragement were invaluable. 
From a career perspective, I have since had the opportunity to apply for 
senior and higher positions and received offers. Probably this would not have 
happened if I had not embarked on the professional doctorate, it is hard to 
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say. However, the understanding gained has helped me in much of my career 
decision making. 
Overall, apart from the specific scientific objectives which I set out from the 
time I commenced this study, I have been able to realise the significance of 
conducting a research to an international standard by applying scientific 
evidence based research. I have also been able to present part of my work at 
the national meetings of two major professional bodies in Ireland (AMLS and 
ACBI). I also hope that there would be no barrier in making new contacts 
amongst my professional peers which would enable me to explore and 
disseminate ideas and ultimately become a more advanced practitioner. 
As for the future, I hope that I will have the opportunity to disseminate and 
build on the work described in this thesis. Finally, I look forward to exciting 
times with attendance at meetings and conferences and, more importantly 
above work, to spend a wonderful time with my wife and the three children, 
one of which arrived two years ago when I was still contemplating on how to 
progress with the project. 
My sincere appreciation goes to my supervisor, Dr Sean O’Broin and to my 
academic supervisor and mentor Professor Graham Mills, and to those who 
helped me throughout this study. 
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APPENDIX F: Stability data HGB, MCV, MCH, MCHC, RET-Y 
and RBC-Y 
Sample  Day Temp oC HGB (g/dL) MCV(fL) MCH(Pg) MCHC(g/dL) RET-Y(ch) RBC-Y(ch) 
S1 1 RT 6.8 69 20.6 29.7 124.6 115.2 
S1 2 4oC 7.7 67.3 20.4 31.2 124.4 115.6 
S1 3 20oC 8 68.6 20.9 30.5 126 115.3 
S1 4 30oC 7.6 76 21.3 28.3 126.9 116.1 
S2 1 RT 14.9 94.7 31.5 33.3 189.1 176.3 
S2 2 4oC 15.3 94.6 31.8 33.5 189.3 177.7 
S2 3 20oC 15.3 97.7 31.8 32.8 189.1 178.6 
S2 4 30oC 15.5 104.8 32 31.1 189.5 178 
S3 1 RT 13.2 97.7 33.6 34.4 189.6 178.1 
S3 2 4oC 13.4 95 33.5 35.4 189.1 178.4 
S3 3 20oC 13.4 98.8 33.7 33.3 188 177.9 
S3 4 30oC 13.3 108.4 34.7 30.4 182 177.7 
S4 1 RT 12 77.2 25.1 32.4 169.4 157.8 
S4 2 4oC 12.4 76.2 25.3 32.9 171.1 157.3 
S4 3 20oC 12.4 79 25.4 31.5 170.6 158.1 
S4 4 30oC 12.3 86.5 26.5 28.7 170.9 158.3 
S5 1 RT 11.1 74.5 23 30.9 161.4 149.6 
S5 2 4oC 11.5 73.7 22.8 31.5 161.7 149.3 
S5 3 20oC 11.4 77.1 23.3 23.3 162.1 150.1 
S5 4 30oC 11.4 80.2 23 28.6 161.4 150.3 
S6 1 RT 15.4 78.1 26.7 34.2 180.4 173.3 
S6 2 4oC 15.6 78.3 26.8 34.1 180.6 173.3 
S6 3 20oC 15.7 82.8 26.7 32.3 180.9 173.2 
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S6 4 30oC 15.7 87.2 27.1 30.8 180.3 273.7 
S7 1 RT 12.3 98.1 33.1 33.7 171.8 156 
S7 2 4oC 13.2 96.7 33.4 34.6 171.6 156.1 
S7 3 20oC 12.9 100.3 32.9 32.8 171 156.6 
S7 4 30oC 12.5 107.1 32.5 34.4 171.1 157 
S8 1 RT 13.9 96.1 31.8 33.1 190.5 177 
S8 2 4oC 14.5 95.6 31.8 33.3 190.3 177.3 
S8 3 20oC 14.3 99.6 31.6 31.8 190.5 177.1 
S8 4 30oC 14.5 105.7 32 30.3 190.8 177.4 
S9 1 RT 11.1 96.7 32 33.1 180 164.4 
S9 2 4oC 11.3 97.4 32.3 33.2 181.3 165.3 
S9 3 20oC 11.4 99.1 32.4 33.6 180.6 165.1 
S9 4 30oC 11.3 104.5 32.2 32.7 180.8 164.8 
S10 1 RT 8.6 87.3 27.2 31.2 166.9 160.1 
S10 2 4oC 8.8 88.5 27.6 31.4 166.1 159.3 
S10 3 20oC 8.8 96.7 27.5 31.6 167.2 160.2 
S10 4 30oC 9 99.7 27.9 31.8 167.3 161.4 
S11 1 RT 11.3 85.7 23.3 27.3 188.1 175.6 
S11 2 4oC 11.5 88.1 23.6 28 187.4 175.8 
S11 3 20oC 11.7 93.6 23.7 27.6 188.1 174.6 
S11 4 30oC 11.3 97.4 23.8 27.5 188.8 175.1 
S12 1 RT 9.6 100 29.2 28.7 178.3 168.1 
S12 2 4oC 9.7 102.3 29.5 28.5 178.4 168.3 
S12 3 20oC 9.4 105.4 29.1 28.4 177.4 168.7 
S12 4 30oC 9.8 108.4 29 28.1 177.6 168.4 
S13 1 RT 10.4 92.7 29.1 31.5 165.3 155.6 
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S13 2 4oC 10.4 95.1 29.3 31.7 166 155.4 
S13 3 20oC 10.7 98.1 29.1 31.3 165.4 156.7 
S13 4 30oC 10.3 99.3 29.6 31.5 165.7 155.3 
S14 1 RT 7.9 117.6 20.7 17.6 180.7 172.3 
S14 2 4oC 7.7 118.6 20.6 17.8 181.1 173 
S14 3 20oC 7.7 119 20.8 17.5 180.4 172.6 
S14 4 30oC 7.5 119.2 21.2 17.9 180 173.1 
S15 1 RT 14.5 91.6 29.7 32.4 178.5 165.4 
S15 2 4oC 14.3 93.4 29.5 32.6 178.1 164.8 
S15 3 20oC 14.4 95.9 29.7 32.8 179.1 164.9 
S15 4 30oC 14.1 97.1 29.5 32.5 178.8 166 
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APPENDIX G: Beckmann Coulter Access principles of serum 
ferritin assay 
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APPENDIX H: R&D Systems Quantikine® IVD analysis for 
sTfR, including plates and graphs. 
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APPENDIX I:  Pilot study results - (RET-He and sTfR in ACD and ID) 
Variables Male (n= 55) 
Mean difference (SD) 
Female (n = 82) 
Mean difference (SD) 
Haematological 
parameters 
6 (23) 6.1 (28) 
Serum ferritin 104 (24.3) 67 (26.8) 
 
  
